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I. INTRODUCTION 
Functional genome research is conducted using model organisms such as mice. 
Mice are easy to handle, have a short generation period and a large litter size, and 
can be maintained in standardized conditions. A high number of genotypically and 
phenotypically characterized mouse inbred strains are available to study 
biochemical and physiological aspects of mammalian biology in a defined genetic 
background. In addition, mice can be easily genetically manipulated. Functional 
studies on mouse models are carried out by reverse genetics approaches or by 
forward genetics approaches. Reverse genetics represents transgenic techniques, 
whereas in forward genetics mice exhibiting aberrant phenotypes are analyzed to 
identify the causative mutations. For the generation of a large number of 
randomly mutant mice, the chemical N-ethyl-N-nitrosourea (ENU) is used. ENU 
is a potent mutagen and induces primarily point mutations in the spermatogonial 
stem cells at a frequency of ~150 × 10-5 per locus (Russell et al. 1979). In the 
phenotype-driven ENU mouse mutagenesis projects, screening of the offspring of 
ENU-mutagenized males is performed in the search of altered phenotypes for the 
establishment of novel mouse models for biomedical research (Hrabé de Angelis 
et al. 2000, Nolan et al. 2000). In the phenotype-driven Munich ENU mouse 
mutagenesis project, a high number of dominant and recessive mutant lines with 
aberrant phenotypes were established. In the present study, the mutant lines 
HST014, HST011 (= UREHR2), and HST015 showing nephropathies as well as 
CLP001 exhibiting alopecia, established previously in the Munich ENU project 
were analyzed with the following aims: 
- Molecular genetic examination of the causative mutation. 
- Examination of the basal pathophysiology of the altered phenotype associated 
with the mutation. 
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II. REVIEW OF THE LITERATURE 
2.1 Mice in biomedical research 
After completion of the human genome project, biomedical research focuses to 
unravel the functions of genes. Understanding the gene functions and their roles in 
different organ systems is the task of functional genomics. Mice are the most 
commonly used lab animals to generate animal models for the understanding of 
many aspects of mammalian biology and diseases (Acevedo-Arozena et al. 2008). 
Mice are easy to handle and require less space compared with other lab animals. 
Phylogenetic analysis of the mammalian genomes revealed a high percentage of 
similarity. In addition, a high number of inbred mouse strains having an identical 
genotype in all individuals of the strain are available which provides the 
opportunity for carrying out experiments under standardized and controlled 
conditions leading to valid and reproducible data. The Mouse Genome 
Informatics (MGI) database (http://www.informatics.jax.org) represents a 
comprehensive public resource providing integrated access to curated genetic and 
phenotypic information for thousands of gene mutations in mice (Bult et al. 2008). 
2.2 Single gene vs. multifactorial genetic disorders  
Human and mouse sequence projects predicted 20,000 to 25,000 genes in both 
species. Alteration in genes may lead to abnormalities in the translated protein or 
in the regulatory system which may cause genetic diseases. Genetic diseases can 
be divided in two categories: 1) monogenic single gene diseases, and 2) 
multifactorial complex diseases. Monogenic disorders are caused due to a 
mutation in a single gene; they are inherited in a dominant or recessive manner 
and can be autosomal or sex-linked. The inheritance pattern of monogenic 
disorders is mostly revealed by pedigree analysis of affected families. In contrast, 
multifactorial complex diseases involve the combined action of many genes, show 
non-mendelian inheritance, and are ultimately determined by a number of genetic 
and environmental factors (Fig. 2.1).  
 
 
 
II. Review of the literature     3 
 
Fig. 2.1: Inheritance and outcome of monogenic and complex disorders (taken from: Peltonen and 
McKusick 2001). 
2.2.1 Genetic mapping of monogenic diseases  
The causative mutation of monogenic disorders can be identified by different 
approaches. Sequence analysis of candidate genes can be carried out which are 
chosen based on the phenotypic characterization of the disease without prior 
knowledge of the chromosomal position of the genes. For example, globin gene 
mutations responsible for certain forms of anemia were identified using this 
approach. This strategy relies on detailed informations of the disease and the 
affected gene. A combined strategy can be carried out by using informations 
about the chromosomal site of a disease locus as well as of a candidate gene locus 
which is chosen based on the known or predicted biological function (Xu and Li 
2000). Once the disease locus and the candidate gene locus are mapped on the 
identical chromosomal region, sequence analysis and/or expression analysis is 
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carried out for the identification of the causative mutation (Moore and Nagle 
2000).  
If suitable candidate genes as well as the chromosomal site of the disease locus 
are not known, identification of the causative mutation starts with the mapping of 
the chromosomal region of the mutant gene (linkage analysis, positional cloning). 
High-density chromosome maps of polymorphic genetic markers have been 
developed for several mammals including the mouse. Linkage analysis aims to 
identify genetic markers that are linked to the causative mutation. Therefore, 
phenotypically mutant mice with the genetic background of an inbred strain are 
crossed for two generations with another inbred strain exhibiting a normal 
phenotype of the trait in question. For the mapping of a dominant mutation, 
heterozygous mutant animals are mated to the second inbred strain. The G1 
offspring are phenotypically classified into two categories, the phenotypic mutant 
and the phenotypic wild-type animals. Phenotypic mutant G1 mice are 
backcrossed to wild-type mice of the second inbred strain. Mapping of recessive 
mutations is carried out by mating of homozygous mutant animals with wild-type 
animals of the second inbred strain and the G2 generation is produced by 
intercrossing of G1 offspring. For both dominant and recessive mutations, the G2 
offspring are again phenotypically characterized. Usually, phenotypically mutant 
G2 animals are used for the genotype analysis with genome-wide polymorphic 
markers to find the chromosomal position of the causative mutation. Single-
nucleotide polymorphisms (SNPs) of a large number of inbred strains are 
available as polymorphic genetic marker for the genetic mapping of mutations 
(http://www.ensembl.org/Mus_musculus/, http://mousesnp.roche.com/cgi-
bin/msnp_public.pl, http://www.broad.mit.edu/snp/mouse/, 
http://www.nervenet.org/MMfiles/MMlist.html, http://snp.gnf.org, 
http://www.ncbi.nlm.nih.gov/SNP/MouseSNP.cgi.). Further fine mapping of the 
identified defined chromosomal region with additional genetic markers is carried 
out. When linkage of the mutant phenotype and the chromosomal region is 
successfully done, suitable candidate genes are selected for sequence analysis 
(Silver 1995). 
2.2.2 Genome-wide association studies (GWAS) 
Genome-wide association studies (GWAS) involve the analysis of the genome of 
a high number of patients exhibiting a disease of interest with a dense array of 
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polymorphic genetic markers compared to an unaffected control population for 
identifying the genetic variations associated with the particular disease (Lander 
2011, and refs. therein). High density, strain-specific single nucleotide 
polymorphism (SNP) data sets like the mouse HapMap resource 
(http://www.mousehapmap.org), the Broad Institute 149 K SNP Hapmap (Frazer 
et al. 2007; http://www.broadinstitute.org/) as well as the Wellcome-CTC Mouse 
Strain SNP Genotype Set (http://mus.well.ox.ac.uk/mouse/INBREDS) are freely 
accessible to design SNP arrays to carry out GWAS in mice. There are also some 
commercially arrays available like the JAX® Mouse Diversity Genotyping Array 
and the Affymetrix® Mouse Diversity Genotyping Array. GWAS can be 
performed on outbred stocks (Yalcin et al. 2010), on inbred and recombinant 
inbred strains (Bennett et al. 2010) as well as on heterozygous stock mice (Valder 
et al. 2006). Outbred stocks are defined as closed populations of genetically 
variable animals that are bred using defined strategies to maintain maximum 
heterozygosity (Festing 1993). Recombinant inbred strains are derived from the 
systematic inbreeding of randomly selected pairs of G2 hybrid mice produced 
from a cross between two inbred strains (Justice et al. 1992). Su et al. (2010) 
performed GWAS in 370 mice from 19 mouse strains for more than 1,000 
expression traits. The results showed that the statistical power of GWAS was low 
and false-positive associations were frequent. In another mouse GWAS study, 18 
genes with significant association to defined SNPs were identified for the 
phenotype of ventilator-induced lung injury (VILI). Of these, the four genes 
Asap1, Adcy8, Wisp1, and Ndrg1 are located in a single region (64.1-66.7 Mb) on 
chromosome 15 (Li et al. 2010). Another GWAS performed in inbred mouse 
strains for the analysis of lung tumor susceptibility, showed the association of 
SNP rs3681853 on Chromosome 5 for spontaneous tumor incidence, of two SNPs 
in the pulmonary adenoma susceptibility 1 (Pas1) locus for urethane-induced 
tumor incidence and of SNP rs4174648 on Chromosome 16 for urethane-induced 
tumor multiplicity. However, linkage analysis showed that only the Pas1 locus 
had a significant effect. In summary, GWAS in mouse inbred strains often show 
false-positive results. Therefore, GWAS combined with linkage analysis may 
produce more significant results (Manenti et al. 2009). In humans, genome-wide 
association studies have identified more than 350 common variants associated 
with risk alleles that contribute to a wide range of complex diseases (Lander 2011, 
Table 2.1). 
II. Review of the literature     6 
Table 2.1: Number of loci identified for different phenotypes in GWAS in humans 
(taken from: Lander 2011) 
Phenotype Number of GWAS loci Proportion of heritability explained (%) 
Type 1 diabetes 41 ∼60 
Fetal haemoglobin level 3 ∼50 
Macular degeneration 3 ∼50 
Type 2 diabetes 39 20-25 
Crohn’s disease 71 20-25 
LDL and HDL levels 95 20-25 
Height 180 ∼12 
LDL: low density lipoprotein; HDL: high density lipoprotein 
2.2.3 Exome sequencing 
With the advent of next-generation sequencing technologies, cost of DNA 
sequencing decreased. Sequencing of the protein coding regions of the genome is 
by far cheaper than whole genome sequencing as the coding regions only 
represent ∼ 1% or ∼ 30 Mb of the whole genome known as exome. In total, about 
180,000 exons are found in the human genome (Ng et al. 2009). Furthermore, 
about 85% of the disease-causing mutations are found in the coding regions (Choi 
et al. 2009). Therefore, exome sequencing is performed to identify genes 
underlying rare monogenic diseases and to discover the coding variants associated 
with common diseases (Coffey et al. 2011). It is a powerful method to identify 
new disease-causing variants in small kindreds for phenotypically and genetically 
heterogeneous disorders where traditional linkage studies are not feasible 
(Bilgüvar et al. 2010, Ng et al. 2010). The consensus coding sequence (CCDS) 
database is mostly targeted by commercial exome capture reagents. The two most 
widely used commercial kits are the NimbleGen Sequence Capture 2.1M Human 
Exome Array (http://www.nimblegen.com/products/seqcap) and the Agilent 
SureSelect Human All Exon Kit (http://www.genomics.agilent.com). Recently, 
Agilent Technologies introduced the Agilent SureSelectXT Mouse all Exon Kit 
which is the first commercial system for the targeted enrichment of a model 
organism exome (http://www.genomics.agilent.com).  
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2.3 Mouse models for functional genome analysis 
Functional studies on mouse models are carried out by reverse genetics 
approaches or by forward genetics approaches (Fig. 2.2). In the reverse genetics 
approaches (gene to phenotype), a DNA sequence of interest is used by transgenic 
techniques which results in the generation of genetically modified mice. Additive 
gene transfer including RNA interference and random insertional mutagenesis as 
well as gene knockout and knockin strategies can be carried out to achieve genetic 
modifications. However, the resulting phenotype due to the genetic modification 
in mouse models does not always reflect the pathophysiology of human diseases. 
Therefore, the complementary forward genetics approach (phenotype to gene) is 
also used to establish additional mouse models for human diseases. The forward 
genetics approach includes the examination of a large number of animals for 
altered phenotypes caused by spontaneous or induced mutations. Mice exhibiting 
altered phenotypes are further bred to establish a mutant line, and subsequently 
the mutant lines are analyzed for the mutations causing the altered phenotypes 
(Hrabé de Angelis et al. 2000, Nolan et al. 2000).  
 
Fig. 2.2: Strategy of the forward genetics and reverse genetics approaches. In forward genetics, 
mice are analyzed from phenotype to gene, whereas in reverse genetics from gene to phenotype. 
2.4 ENU mutagenesis 
2.4.1 History and mechanism of action 
N-ethyl-N-nitrosourea (ENU) is a synthetic alkylating compound which is toxic 
and carcinogenic to the cells (Fig. 2.3). It is a potent mutagen, and primarily 
affects spermatogonial stem cells. It induces random point mutations in the 
spermatogonial stem cells at a frequency of ~150 × 10-5 per locus in mice (Russell 
et al. 1979). It does not require any metabolic processing for its activation (Singer 
and Dosahjh 1990).  
 
Reverse genetics
Forward genetics
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Fig. 2.3: Chemical formula of ENU 
ENU transfers its ethyl group to oxygen and nitrogen reactive sites of the 
nucleotides (Table 2.2, Noveroske et al. 2000). 
Table 2.2: Reactive sites of ENU alkylation (taken from: Noveroske et al. 2000) 
Nucleotide Reactive sites 
Adenine N1, N3, and N7 
Thymine O2, O4, and N3 
Guanine O6, N3, and N7 
Cytosine                        O2 and N3 
 
The ethylated nucleotide is not recognised correctly during DNA replication 
which results in mispairing to a non-complementary nucleotide (Fig. 2.4).  
 
Fig. 2.4: Mechanism of action of ENU. A) Alkylation of thymine results in the formation of O4-
Ethylthymine which is recognised as cytosine and mispairs with guanine. B) Mispairing leads to 
the corresponding base exchange during DNA replication (taken from: Noveroske et al. 2000). 
After two rounds of DNA replication, a single base pair substitution occurs which 
is not identified by the cellular DNA repair systems and therefore results in a 
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single base change mutation in the DNA (Bielas and Heddle 2000, Noveroske et 
al. 2000). 
2.4.2 ENU mouse mutagenesis  
The alkylating agent ENU is a powerful mutagen for the production of randomly 
mutant mouse models. Screening for ENU-induced mutations can be carried out 
by two strategies, the phenotype-driven screen and the gene-driven screen. In a 
phenotype-driven screen, a large number of offspring of ENU-mutagenized males 
are screened for the phenotypes of interest. Mice showing aberrant phenotypes are 
further bred to wild-type animals, and offspring are screened for the desired 
phenotype. Transmission of the altered phenotype to the subsequent generation 
shows a genetic mutation as the cause for the altered phenotypes (Balling 2001, 
Nolan et al. 2000). No assumptions are made about the genetic basis of a 
particular phenotype. The causative mutation of the altered phenotype is identified 
by linkage analysis (see 2.2.1).  
The ENU gene-driven approach is performed on DNA by establishing both a 
sperm and a DNA archive from G1 offspring of ENU-mutagenized males (Coghill 
et al. 2002). Screening the DNA archive for mutations in a gene of interest 
followed by the recovery of mutant mice from the corresponding frozen sperm 
sample by in vitro fertilization (IVF) allows the subsequent phenotypic 
characterization of the mutation (Fig. 2.5).  
DNA archive centres include the MRC Harwell UK (FESA), the German ENU 
mouse mutagenesis screening project, the RIKEN Bioresource Center and the 
Australian Phenomics facility (Acevado-Arozina et al. 2008). Alternatively, ENU 
gene-driven approaches can be performed on ENU treated mouse ES cells. 
Mutagenized ES cells are screened for mutations in a gene of interest and a 
parallel frozen cell archive can be used to generate mutant mice (Chen et al. 2000, 
Munroe et al. 2000). 
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Fig. 2.5: Scheme for an ENU gene-driven screen. a) A DNA archive of G1 mice derived from 
ENU-mutagenized males is screened for mutations and mutant mice are recovered by in vitro 
fertilization (IVF) from the frozen sperm. b) A library of ENU-treated ES cells is screened for 
ENU mutations. Once a mutated clone is identified, ES cells are microinjected into mouse 
blastocysts to generate mutant mice for further examinations (taken from: Acevado-Arozina et al. 
2008).  
For ENU mutagenesis, one mutation has been estimated to occur in 1.0-2.5 Mb 
(Aigner et al. 2008, and refs. therein). Thus, G1 offspring of ENU-mutagenized 
males harbour less than 100 potentially functional mutations. A founder G1 
mouse with an interesting phenotype is backcrossed using wild-type mice of the 
same inbred strain to eliminate additional mutations. The number of mutations 
will decline on average by 50% with each backcross generation; as the resulting 
genome will harbour about 97% of non-mutagenized genome of the recipient 
animals after five backcrosses (Keays et al. 2006). 
After identifying the putative causative mutation, the proof that the sequenced 
mutation is the causative mutation has to be produced by functional analysis, e.g. 
by expression analysis of the affected gene, by performing complementation tests 
with another mutant allele or by rescue of the wild-type function of the gene in 
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transgenic mice. The mutants may carry loss-of-function, dominant-negative, 
hypomorphic, or gain-of-function alleles of the affected genes (Caspary and 
Anderson 2006). 
2.4.3 Spectrum of ENU-induced mutations  
ENU mostly generates random genome-wide point mutations by base 
substitutions. Around 70-85% of the base substitutions are A-T to T-A 
transversions or A-T to G-C transitions (Table 2.3, Noveroske et al. 2000, 
Takahasi et al. 2007). Conversely, the G-C to C-G transversion appears less often 
(Augustin et al. 2005). To a lower extent, few small deletions have been also 
reported as a consequence of ENU mutagenesis (Shibuya and Morimoto 1993).  
Table 2.3: Genetic nature and frequencies of mutations found in ENU projects 
(taken from: Barbaric et al. 2007) 
 
About 70% non-synonymous amino acid exchanges occurred due to ENU-
induced point mutations. 65% of these are missense amino acid exchanges and the 
rest are nonsense or splice mutations at the protein level (Table 2.4, Barbaric et al. 
2007, Justice et al. 1999, Takahasi et al. 2007).  
Table 2.4: Consequences of ENU-induced mutations at the protein level (taken 
from: Barbaric et al. 2007) 
 Missense Nonsense Splicing 5’, 3’ UTR 
Destroy 
start site 
Make 
sense Frameshift 
Phenotype-
driven (%) 
58.9 
 
16.6 
 
21.9 
 
0 
 
1.3 
 
0 
 
1.3 
 
Gene-driven 
(%) 
83.3 
 
6.5 
 
5.7 
 
3.7 
 
0 
 
0.8 
 
0 
 
 
 AT to  
TA 
AT 
 to GC 
AT to  
CG 
GC to 
AT 
GC 
 to TA 
GC to 
CG Insertion Deletion 
Phenotype-
driven (%) 
29.5 
 
30.2 
 
7.4 
 
18.1 
 
10.7 
 
1.3 
 
0.7 
 
2.0 
 
Gene-driven 
(%) 
27.3 
 
37.0 
 
3.9 
 
18.7 
 
12.1 
 
0.8 
 
0 
 
0.4 
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2.4.4 Outcome of the ENU mouse mutagenesis projects 
Major ENU mouse mutagenesis projects have been performed as phenotype-
driven as well as gene-driven screens for the generation of novel mutant models 
(Table 2.5).  
Table 2.5: Centres running ENU mouse mutagenesis projects (taken from: Cordes 
2005) 
ENU centre Website Genetic approach Genetic region 
ENU mutagenesis 
programme MRC 
Harvell UK 
http://www.har.mrc.ac.uk/research/mutagenesis/ 
 
Dominant 
Recessive 
Genome-wide 
Chr 13 36H 
Munich ENU mouse 
mutagenesis project 
Germany 
http://www.helmholtz-muenchen.de/en/ieg/group-
functional-genetics/enu-screen/index.html  
Dominant 
Recessive 
Genome-wide 
Genome-wide 
Australian phenomics 
facility 
http://www.apf.edu.au/  Recessive Genome-wide 
Baylor College of 
Medicine Mouse 
Genome project 
http://www.mouse-
genome.bcm.tmc.edu/ENU/ENUHome.asp  
Recessive Chr 11 
Chr 4 
Centre for Modeling 
Human disease 
http://www.cmhd.ca/  Dominant Genome-wide 
Genomics institute of 
the Novartis Research 
foundation 
http://www.gnf.org/  Recessive Genome-wide 
Jackson Laboratory 
Neuroscience 
Mutagenesis Facility 
http://nmf.jax.org/  Dominant 
Recessive 
Recessive 
Genome-wide 
Genome-wide 
Chr 5 
Jackson Laboratory 
Mouse Heart, Lung, 
Blood and Sleep 
Disorders Center 
http://pga.jax.org/  Dominant 
Recessive 
Genome-wide 
Genome-wide 
Molecular 
Neurobiology at 
Northwestern 
University 
http://www.neurobiology.northwestern.edu/  Dominant 
Recessive 
Genome-wide 
Genome-wide 
Mutagenesis Project 
at MRI 
http://www.montana.edu/wwwmri/index.html  Recessive Genome-wide 
Oak Ridge National 
Laboratory 
http://www.ornl.gov/  Recessive Chr 7, chr 10, 
chr 15 & chr X 
 
RIKEN Mutagenesis 
Center 
http://www.brc.riken.jp/lab/gsc/mouse/  Dominant 
Recessive 
Genome-wide 
Genome-wide 
Tennessee Mouse 
Genome Consortium 
http://www.tnmouse.org/  Recessive Chr 7, chr 10, 
chr 15 & chr X 
University of 
Pennsylvania, 
Philadephia 
http://www.med.upenn.edu/ins/faculty/bucan.htm  Recessive Chr 5 
 
Search for published ENU-induced mutants (as of 31.03.11) in the “phenotypes 
and alleles” MGI database 
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(http://www.informatics.jax.org/searches/allele_form.shtml) revealed 2,282 alleles 
and 1,823 genes/markers. Among them, 73 alleles and 61 genes/markers are 
described for influencing the renal or urinary system as primary or secondary 
phenotype derived from phenotypic-driven or gene-driven approaches. 
2.5 The phenotype-driven Munich ENU mouse mutagenesis project 
The Munich ENU mouse mutagenesis project has been established for the 
genome-wide screen for dominant and recessive mutations in C3HeB/FeJ (C3H) 
inbred mice. Male C3H mice (10 weeks old, G0) are treated with three 
intraperitoneal injections of 90 mg/kg ENU at weekly intervals (Hrabé de Angelis 
et al. 2000). The treated male mice are mated with wild-type C3H females and the 
G1 offspring are screened for dominant mutations. After carrying out a defined 
breeding scheme (see Fig. 2.6), G3 mice are screened for recessive mutations. A 
large number of mutant mouse lines have been established in different phenotypic 
screens. The phenotypic screens are done in the German Mouse Clinic (GMC), 
which is an open-access technology platform established for the comprehensive 
phenotyping of mutant lines (Fuchs et al. 2009, Gailus-Durner et al. 2005). 
2.5.1 The clinical chemical screen for dominant and recessive mutations 
The Chair for Molecular Animal Breeding and Biotechnology (Prof. Dr. E. Wolf), 
LMU München conducts the clinical chemical screen in the Munich ENU mouse 
mutagenesis project. The focus of the clinical chemical screen is to detect 
alterations in blood parameters (substrates, enzyme activities, electrolytes) as well 
as haematological changes by common high-throughput laboratory diagnostic 
procedures. The list of parameters used in the clinical chemical screen is given in 
Table 2.6 (Rathkolb et al. 2000). More than 15,000 G1 offspring and 500 G3 
pedigrees have been screened for alterations in clinical chemical parameters. 
Table 2.6: Clinical chemical plasma parameters used (taken from: Rathkolb et al. 
2000) 
Enzyme Activities Alkaline phosphatase (AP), α-amylase, creatine 
kinase (CK), aspartate-aminotransferase (AST), 
alanine-aminotransferase (ALT), lipase, c-reactive 
protein 
Substrates  Glucose, cholesterol, triglycerides, total protein, uric 
acid, urea, creatinine, ferritin, transferritin, lactose, 
low density lipoprotein 
Electrolytes  Potassium, sodium, chloride, calcium, inorganic 
phosphate (Pi) 
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2.5.2 Establishment of mutant lines in the clinical chemical screen 
The screen for dominant mutations is performed on G1 animals that are derived 
from the mating of ENU-mutagenized G0 males to wild-type C3H females (Fig. 
2.6).  
 
Fig. 2.6: ENU mutagenesis and breeding strategies for the screening for dominant and recessive 
mutation. ENU treated male (G0) mice are mated to female wild-type C3H mice to produce G1 
mice. The dominant mutations are screened in the G1 offspring and the recessive mutations are 
screened in the G3 offspring produced from the backcross of G2 animals with G1 mice. Black 
triangles: causative mutation; light triangles: non-causative mutations (taken from: Aigner et al. 
2008). 
Animals with an aberrant phenotype associated with blood parameters are re-
examined for the mutant phenotype. Animals showing the aberrant phenotype also 
in the second measurement are considered to be mutant for the screened 
parameter. Inheritance of the observed mutant phenotype is tested on G2 mice, 
which are derived from the mating of the G1 mice exhibiting the altered 
phenotype and wild-type mice. The appearance of the aberrant phenotype in G2 
mice confirms that the mutant phenotype is caused by a dominant mutation and 
allows the generation of a mutant line. 
The screen for recessive mutations is performed on G3 mice, which are produced 
in a two-step breeding scheme from G1 mice. Phenotypically normal G1 males 
are mated to wild-type females for the production of G2 animals. Subsequently 
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G2 females are backcrossed to the G1 male to produce the G3 mice (Fig. 2.6). G3 
mice with an aberrant phenotype associated with blood parameters are re-
examined for the mutant phenotype. Animals showing the aberrant phenotype also 
in the second measurement are considered to be mutant for the screened 
parameter. Inheritance of the aberrant phenotype is confirmed in G5 mice. 
Therefore, the phenotypically mutant G3 mice supposed to harbour a homozygous 
recessive mutation are mated to wild-type mice for the production of the 
presumably heterozygous mutant G4 mice with an inconspicuous phenotype. 
Intercrossing of the G4 heterozygous mutant mice is performed to produce G5 
animals. The appearance of the aberrant phenotype in G5 mice confirms that the 
mutant phenotype is caused by a recessive mutation and allows the establishment 
of a mutant line. Provisional names are given to the established mutant lines, 
which are replaced according to the official nomenclature after identification of 
the mutation (http://www.informatics.jax.org/mgihome/nomen/index.shtml). 
2.5.3 Analysis of the causative mutation 
Linkage analysis is carried out to find the chromosomal position of the causative 
mutation after the establishment of a mutant line. C57BL/6 or BALB/c is used as 
second inbred strain for the linkage analysis in the Munich ENU mouse 
mutagenesis project. The breeding strategy to map the dominant mutation is given 
in Fig. 2.7. Phenotypically heterozygous mutant animals are mated to the second 
inbred strain. Phenotypically mutant G1 hybrid mice are backcrossed to wild-type 
mice of the second inbred strain (Aigner et al. 2008). The G2 offspring are 
phenotypically classified as mutant mice and wild-type mice. Usually, DNA 
samples from phenotypically mutant G2 mice are used in the genetic analysis 
using a panel of genome-wide polymorphic markers.  
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Fig. 2.7: Breeding strategy for mapping dominant mutations. Phenotypically heterozygous mutant 
animals are mated to a second inbred strain. G1 hybrid offspring showing the mutant phenotype 
are backcrossed to wild-type mice of the second inbred strain. Triangles: causative dominant 
mutation (taken from: Aigner et al. 2008). 
For mapping a recessive mutation, phenotypically homozygous mutant animals 
are mated with a second inbred strain and the resulting G1 hybrid mice with 
inconspicuous phenotype are intercrossed for the production of the G2 offspring 
(Fig. 2.8).  
 
Fig. 2.8: Breeding strategy for mapping recessive mutations. Phenotypically homozygous mutant 
animals are mated with a second inbred strain and the resulting G1 hybrid mice are intercrossed 
for the production of the G2 offspring. Triangles: causative recessive mutation (taken from: Aigner 
et al. 2008). 
 
G1 
 
G2 
G1 
 
G2 
II. Review of the literature     17 
G2 animals are phenotypically classified as mutant and wild-type mice. About 
150 genome-wide polymorphic markers are used for the chromosomal mapping of 
the mutation. Further fine mapping with additional polymorphic markers is 
carried out. Subsequently, candidate genes within the identified defined genetic 
interval are analyzed to find the causative mutation for the mutant phenotype. In 
ENU-induced mutant lines, usually a single mutation has been proven to be the 
cause for the mutant phenotype (Barbaric et al. 2007). Causative mutations have 
already been successfully mapped and subsequently identified in many mutant 
lines established in the Munich ENU mouse mutagenesis project (Kemter et al. 
2010, and refs. therein).  
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III. RESEARCH METHODOLOGY 
3.1 ENU-induced mutant lines analyzed in this study 
The mutant lines HST014, HST011, and HST015 showing increased plasma urea 
values established in the clinical chemical screen, as well as line CLP001 
exhibiting alopecia as primary phenotypic alterations were analyzed in this study 
(Table 3.1). 
Table 3.1: ENU-induced mutant lines analyzed in this study 
Line Aberrant phenotype Founder animal Year Inheritance 
HST014 Increased plasma urea G1 male ID 10295828 2006 Dominant 
HST011 Increased plasma urea G3 male ID 20033899 2000 Recessive 
HST015 Increased plasma urea G1 male ID 10174676 2006 Dominant 
CLP001 Alopecia G1 female ID 20020972 2000 Dominant 
Increased plasma urea values (>70 mg/dl for males and >65 mg/dl for females as cut-off values) 
3.1.1 Line HST014 
Line HST014 harbours a dominant mutation. Four-month-old phenotypically 
heterozygous mutant mice showed increased plasma urea values (>70 mg/dl for 
males and >65 mg/dl for females as cut-off values) as compared with littermate 
controls. 
3.1.2 Line HST011 
Line HST011 (= UREHR2) harbours a recessive mutation. Phenotypically 
homozygous mutant animals exhibited increased plasma urea and creatinine levels 
as compared to control littermates. In addition, four-month-old phenotypically 
homozygous mutants showed a decreased absolute and relative kidney weight 
(Fig. 3.1). Light microscopy showed no alterations in the kidneys of the 
phenotypically mutant animals (Aigner et al. 2007).  
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Fig. 3.1: Macroscopic appearance of the kidneys of HST011 mice. Kidneys of phenotypically 
homozygous mutant animals were smaller compared to phenotypically wild-type littermates (taken 
from: Aigner et al. 2007). 
For the chromosomal mapping of the causative mutation, phenotypically 
homozygous mutant animals on the inbred C3H genetic background were bred 
with BALB/c inbred mice. The phenotypically inconspicuous heterozygous 
mutant G1 mice were intercrossed for the production of the G2 generation. G2 
offspring were screened for increased plasma urea levels (>70 mg/dl for males 
and >65 mg/dl for females as cut-off values) at the age of 12 and 15 weeks, and 
subsequently 48 phenotypically mutant animals were selected for the linkage 
analysis. Linkage analysis was carried out using a panel of 116 genome-wide 
polymorphic markers in collaboration with the Institute of Experimental Genetics 
(Prof. Dr. M. Hrabé de Angelis), Helmholtz Zentrum München. Linkage analysis 
mapped the causative mutation to chromosome 7. 
3.1.3 Line HST015 
Line HST015 has a dominant mutation. Twelve-week-old phenotypically 
heterozygous mutant mice showed increased plasma urea values (>70 mg/dl for 
males and >65 mg/dl for females as cut-off values) as compared with littermate 
controls. 
3.1.4 Line CLP001 
Line CLP001 harbours a dominant mutation. Phenotypically heterozygous mutant 
mice showed alopecia. Onset of hair loss started from 3 weeks of age from the 
back. For linkage analysis, phenotypically heterozygous mutant mice on the 
inbred C3H genetic background were bred for two generations with C57BL/6 
inbred mice. Phenotypically heterozygous mutant G2 mice exhibiting alopecia 
were selected for linkage analysis. Linkage analysis on 46 phenotypically mutant 
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G2 animals with 94 genome-wide polymorphic markers was carried out. The 
causative mutation was mapped on chromosome 11. Fine mapping was carried out 
with additional polymorphic markers in the defined chromosomal region and 
confirmed the mapping results. 
3.2 Animal husbandry and maintenance of the mutant lines 
The mutant lines were maintained in the mouse facility at the Chair for Molecular 
Animal Breeding and Biotechnology, Moorversuchsgut, Oberschleißheim under a 
controlled specific-pathogen-free (SPF) hygiene standard according to the 
Federation of European Laboratory Animals Science Associations (FELASA) 
protocols (Nicklas et al. 2002; http://www.felasa.eu/). Mouse husbandry was done 
under standard environmental conditions (22°C, 55% relative humidity, 12 h light 
: 12 h dark cycle) and mice were provided a standard rodent diet (V1124; Ssniff, 
Soest, Germany) and water ad libitum. All animal experiments were conducted 
under the approval of the responsible animal welfare authority (Regierung von 
Oberbayern). The dominant mutant lines HST014, HST015, and CLP001 were 
maintained by mating phenotypically heterozygous mutant animals to wild-type 
C3H mice. The recessive mutant line HST011 was maintained by mating 
phenotypically homozygous mutant animals to wild-type C3H mice and 
subsequently intercrossing of the heterozygous mutant offspring without aberrant 
phenotype. Offspring were weaned three weeks post partum and marked by ear 
punching. 
3.3 Analysis of the causative mutation 
3.3.1 Line HST014 
3.3.1.1 Linkage analysis 
Phenotypically heterozygous mutant mice on the inbred C3H genetic background 
with increased plasma urea levels were bred to BALB/c inbred mice. The G1 
hybrid offspring were examined for increased plasma urea levels at the age of 9, 
12, and 15 weeks. G1 animals showing increased plasma urea values (>70 mg/dl 
for males and >65 mg/dl for females as cut-off values) were bred with BALB/c 
mice. The G2 animals were analyzed for increased plasma urea levels at the age of 
9, 12, and 15 weeks and classified as phenotypically heterozygous mutants 
exhibiting increased plasma urea values and wild-type mice. Tail samples of G2 
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mice were collected and stored at -80˚C. Linkage analysis was performed using a 
panel of 113 genome-wide polymorphic markers on the DNA samples of 45 
phenotypically mutant G2 animals in cooperation with the Institute of 
Experimental Genetics (Prof. Dr. M. Hrabé de Angelis), Helmholtz Zentrum 
München. 
3.3.1.2 Fine mapping and selection of candidate genes 
Fine mapping was performed by using additional polymorphic microsatellites and 
SNP markers which are described to exhibit different alleles for C3H and BALB/c 
mice (http://www.informatics.jax.org/; http://www.ncbi.nlm.nih.gov) and which 
cover the previously defined chromosomal region. The PCR primers (Table 3.2) 
were designed according to the available sequence data 
(http://www.informatics.jax.org/; http://www.ensembl.org/) and were ordered for 
synthesis (Thermo Fisher Scientific, Ulm, Germany).  
Table 3.2: Polymorphic markers of chromosome 18 used for fine mapping in the 
line HST014  
Marker name Chr. Position (Mb) Forward primer (5’-3’) Reverse primer (5’-3’) 
rs52303422 9.5 caggacagttgtcacaggac tcccatcatgtactgtaagcac 
rs52534573 11.2 ccctccgttcccactttctc tcaggatccatgtcaacaaag 
rs46961948 11.4 cagcctttgtacatggtgac tacagtggctgtcgtagtttac 
rs52391350 12.9 actgtgtgctttagaacacaac gctctctggtgctctctgg 
rs52376653 13.6 tgggatgtatgtagcactc gttttattgagtgtgggag 
rs31073798 14.3 atgaggggaagcgctgaagg cttctgttaagctgtaaaatgc 
rs31158307 14.6 ctgggaaatgccttctcttgc gatgaacttgtgagcccattag 
rs31155567 14.6 gagtggttttggtatcagtg tctcccaacccccctc 
rs31158391 14.6 tctatcctaactgatctagtc ggcttccatgatcagcagg 
rs31243033 17.0 tgaaatgatgaaagaccatataatg caaaggaagatgtttactataaag 
rs31247952 17.0 atatttatttatgtaattaaataac gatttgaaatactattgacag 
rs31220775 17.5 ggcaaagaaccttttcctctc tgtttgtctctctattctg gttg 
D18Mit68 21.5 gcgtgagggttttgtttgtt aatacttccagaaccttagacc 
rs51268966 23.4 agaatttaaggatgaacttt actg ccctgtgatccatccaatagc 
rs52585890 26.1 gtgagtgtatgtatgtatctcag aagttcatgggccagctagc 
D18Mit70 35.0 ctgctagcgtttaccatatagc ctgtggtctcccagccac 
The marker position is given according to http://www.informatics.jax.org/. 
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The microsatellite markers D18Mit68 and D18Mit70 were analyzed by PCR 
whereas the SNP markers were analyzed by using a PCR-RFLP strategy. The 
genes which are located in the identified defined chromosomal region 
(http://www.ensembl.org/) were analyzed for published data about their wild-type 
and mutant function (http://www.informatics.jax.org/). Three genes were selected 
as the candidate genes for the mutant phenotype (Fig. 3.2). 
 
Fig. 3.2: Chromosomal position of the candidate genes for line HST014. The selected genes are 
shown in boxes. The figure is adopted from http://www.ensembl.org/. 
3.3.1.3 Analysis of the candidate genes 
PCR amplifications of the exonic or cDNA sequences of the candidate genes were 
carried out using specific primers (Table 3.3). Subsequently, sequencing of the 
PCR products was carried out. The obtained sequences were compared with 
published database sequences and C3H wild-type sequences.  
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Table 3.3: Candidate genes on chromosome 18 and their primer sequences 
Gene Primer and transcript ID Forward primer 
 (5’-3’) 
Reverse primer 
 (5’-3’) 
Expected 
PCR product 
size (bp) 
Aqp4 E_1(ENSMUST00000079081) ctgtgtctataatgatcaggtacag gctgttgctaccttctagattctg 305 
 E_2(ENSMUST00000079081) aaactgcaagactgcagcctgac tgcaagcacatgaagttctagtac 550 
 E_3(ENSMUST00000079081) tggtagaagactcaagttaaccatg agcttcagggtgaggataaatgag 337 
 E_4(ENSMUST00000079081) tgttcctctgaggagactacagc agaaaccagtgagctaaattacgc 257 
 E_5(ENSMUST00000079081) tatatgcataggttgtccactgag tgtaacaaggtgtgaagcaagaaac 402 
 E_1(ENSMUST00000115856) tcctatgagtgtgaacacatcagg cacctgctcattcacacacctg 232 
 E_2(ENSMUST00000115856) acaggtgtgtgaatgagcaggtg tctctgagagagactgtgagaac 287 
Mep1b P_1(ENSMUST00000082235) agcttgcagctttcatctggaag gaatcagacacactgtcattgtag 612 
 P_2(ENSMUST00000082235) agtcacgtgctgaccgggatg aacagtctgctctccatcg 540 
 P_3(ENSMUST00000082235) agtgcaaagactctggcttcttc ctccgctggttgaacatacgc 660 
 P_4(ENSMUST00000082235) tggccatgtccttggcaacaag tggaaggtctcttttcatttcacc 660 
 E_1(ENSMUST00000115840) tgccttgtcaaccacatgactg gatgacgtctgtatcctcttctg 284 
Kctd1 P_1(ENSMUST00000025992) tgtgcttcaatgtttcaggacag cacaaatgtcccttttctcatattg 861 
 
3.3.1.4 Genotyping of the animals of line HST014 
After identifying the causative mutation, the DNA sequence containing the point 
mutation was analyzed with the NEBcutter V2.0 tool (New England Biolabs, UK; 
http://tools.neb.com/NEBcutter2/). The point mutation resulted in the abolishment 
of the restriction site of the enzyme BsmI in the mutant allele. For the genotypic 
analysis of homozygous mutant, heterozygous mutant and wild-type animals, a 
PCR-RFLP strategy was established. The PCR primers were designed 
encompassing the DNA sequence around the point mutation (Kctd1_F: 5’ 
acggcaaaagtgagagaacctg 3’ and Kctd1_R: 5’ tggaattgcaggcagataatgcc 3’). PCR 
conditions were used as given.  
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Components of the PCR master mixture (1×)          Volume (μl)
Distilled H2O                              
10× PCR buffer      
dNTPs (2 mM)                             
MgCl2 (25 mM)    
Primer Kctd1_F (10 mM)                           
Primer Kctd1_R (10 mM)                          
Taq DNA Polymerase (10 U/μl)        
Genomic DNA (100 ng/μl)                         
15.4 
2.5 
2.5 
2.5 
0.4 
0.4 
0.3 
1.0
 
For restriction enzyme digestion, 5 μl of the PCR products were incubated with 5 
μl master mixture (3.5 μl distilled H2O, 1 μl 10× restriction enzyme buffer, 5 U 
BsmI (Fermentas, St. Leon-Rot, Germany)) at 37˚C for 2 h. Digested PCR 
products were analyzed on a 2% agarose gel stained with ethidium bromide. 
Homozygous mutant mice were produced by mating heterozygous mutant mice on 
the C3H genetic background.  
3.3.2 Line HST011 
3.3.2.1 Fine mapping of chromosome 1  
Fine mapping was carried out on phenotypically mutant animals which exhibited 
the homozygous wild-type genotype for the Umod gene (see 4.2.1). Polymorphic 
markers which are described to have different alleles for C3H and BALB/c were 
selected for chromosome 1 (Table 3.4).  
 
• 94˚C        5 min 
• 94˚C        30 sec 
• 66˚C        45 sec 
• 72˚C        45 sec 
• 72˚C         5 min 
35× 
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Table 3.4: Polymorphic markers used for fine mapping of chromosome 1 in line 
HST011 
Marker name Chr. Position (Mb) Forward primer (5’-3’) Reverse primer (5’-3’) 
D1Mit64 12.8 agtgcattatgaagccccac tcaaattttaaaacaacccatttg  
D1Mit432 24.3 tctgctcttgttctcttctgagg gcagattcatttctctctctataatc 
D1Mit411 33.2 ggaaactggaaaagggggta tagcattgctctttggtttctg 
D1Mit212 40.0 tctcatgaggtgtgtgagtttg ggatccccttgcttcactaa 
D1Mit156 65.8 tctgctgccacttctgag gtgtgtctatggacatggatg 
D1Mit415 88.3 ttggcacatgcctacaactc agaacaccatatattgtgccc 
The marker position is given according to http://www.informatics.jax.org/. 
3.3.2.2 Selection and analysis of the candidate gene 
According to the MGI data (http://www.informatics.jax.org/), the gene Pou3f3 
(Fig. 3.3) was selected as candidate gene for sequence analysis (Table 3.5). 
 
Fig. 3.3: Chromosomal position of the gene Pou3f3 (shown by arrow). The figure is adopted from 
http://www.ensembl.org/. 
Table 3.5: Primer sequences of the candidate gene Pou3f3 (chr. 1, 42.7 Mb) of 
line HST011 
Primer Forward primer 
(5’-3’) 
Reverse primer 
(5’-3’) 
Expected PCR 
product size (bp) 
P_1 gcggctgctgctgcggcg tccgcggtgatgcagcgcgg 560 
P_2 cagcagccgccacagccgc tgaactgcttagcgaactgctc 682 
P_3 gctcaacagccacgaccctc tgctgacagcggctgcggag 658 
The position is given according to http://www.ensembl.org/.   
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3.3.2.3 Genotyping of the animals of line HST011 
Genotyping of the animals of line HST011 was also carried out with PCR-RFLP 
because a restriction site of the enzyme SmlI was abolished due to the causative 
mutation (NEBcutter V2.0 tool; New England Biolabs, UK; 
http://tools.neb.com/NEBcutter2/). Primers were synthesised 5’ and 3’ of the 
causative mutation (Pou3f3_F: 5’ cactggcagtcccaccagc 3’ and Pou3f3_R: 5’ 
agcagcagcggtggttctcg 3’). PCR conditions are shown below.  
Components of the PCR master mixture (1×)           Volume (μl)
Distilled H2O                              
10× PCR buffer      
dNTPs (2 mM)                             
MgCl2 (25 mM)    
Primer Pou3f3_F (10 mM)                           
Primer Pou3f3_R (10 mM)                          
Taq DNA Polymerase (10 U/μl)        
Genomic DNA (100 ng/μl)                         
15.4 
2.5 
2.5 
2.5 
0.4 
0.4 
0.3 
1.0
 
For restriction enzyme digestion, 5 μl PCR products were incubated with 5 μl 
master mixture (analogous to 3.3.1.4) using SmlI at 55˚C for 2 h. The digested 
PCR products were analyzed on a 2% agarose gel and stained with ethidium 
bromide.  
3.3.3 Line HST015 
3.3.3.1 Linkage analysis 
Phenotypically heterozygous mutant mice on the inbred C3H genetic background 
• 94˚C        5 min 
• 94˚C        30 sec 
• 64˚C        45 sec 
• 72˚C        45 sec 
• 72˚C         5 min 
35× 
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with increased plasma urea levels were bred to BALB/c inbred mice. The G1 
hybrid offspring were examined for increased plasma urea values (>70 mg/dl for 
males and >65 mg/dl for females as cut-off values) at the age of 12 and 15 weeks. 
G1 animals showing increased plasma urea values were bred with BALB/c inbred 
mice. The G2 animals were analyzed for increased plasma urea values (>70 mg/dl 
for males and >65 mg/dl for females as cut-off values) at the age of 12, 15 and 18 
weeks and classified as phenotypically heterozygous mutants exhibiting increased 
plasma urea values and wild-type mice. 
3.3.3.2 Fine mapping of chromosome 7 
Fine mapping was carried out on phenotypically mutant G2 mice using 
polymorphic markers of chromosome 7 (Table 3.6). 
Table 3.6: Polymorphic markers used for fine mapping of chromosome 7 in line 
HST015 
Marker name Locus (Mb) Forward primer (5’-3’) Reverse primer (5’-3’) 
D7Mit230 56.7 ggttaactgctttt taaaagtgc acttctgcatgttgccctct   
D7Mit276 69.4 ctgggaggaatgttctccaa atgcccagtgtagaagaaacc 
D7Mit90  87.5 cacaccaagtctccccaact caaaactgacccagagaggc 
D7Mit323 108.0 caccttctaatcctacttcctg ccagaacaggaaatagagtacc 
D7Mit40 123.9 gtcaacagtcaggaaagctgg cagatgcttgtatttgcaaagc 
D7Mit68 132.4 ctcccacacagggtctttgt gatacccaaagtacacctctgtca 
The marker position is given according to http://www.informatics.jax.org/.   
3.3.3.3 Selection and analysis of the candidate genes 
The genes which are located in the identified defined chromosomal region 
(http://www.ensembl.org/) were analyzed for published data for wild-type and 
mutant function (http://www.informatics.jax.org/). The genes Tomt and Chd2 
were selected as candidate genes and used for sequence analysis (Table 3.7). 
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Table 3.7: Candidate genes on chromosome 7 and their primer sequences 
Gene Primer  Forward primer (5’-3’) Reverse primer (5’-3’)  Expected PCR 
product size 
(bp) 
Tomt E2 cagacatgtttgtataagcgtgg aggtaagcagtgggccatgc 472 
 E3 agcacagcaggtttgattctg gaaagaggcctggtctgagc 335 
 E4 taaatcagccagatcccggtg attctgaggtctgcttgaatgg 458 
Chd2 P1 atgcgtggtggccagcagtag catcatcctaggaagcagaaaac 711 
 P2 gcgggtctgagagtgggag gttgctgtaaggagtcttcac 600 
 P3 aatggagatcctagcgatgac tcaaagccacaaatctcggcc 547 
 P4 ggaagatgaagccttgattgg aagagtcatcattcttcaaccg 602 
 P5 aatgcacttataacaacatatgag tgctcctaattagagactgaag 601 
 P6 cttccttaatatcgtgatggag tcctgccagtggtatccatg 596 
 P7 tgaatatttaccgcctggttac atcagagtcgtccgtctcac 599 
 P8 gcctcggattcgcagttccac cagacgagaatcgtcctccac 598 
 P9 tgagatgctgcataaatctatcc atcaccacctttgaccttctc 607 
 P10 aaccagtgagctctcggaagg aatcccggcttgagcccgag 561 
 P11 aagttatataagatggctcataag gtctcggtcgctgttgtactg 474 
 P12 aggaccaccactatggtgacc caacagcagcagcatatccag 599 
 
3.3.4 Line CLP001 
3.3.4.1 Selection and analysis of the candidate gene 
Linkage analysis and fine mapping was done earlier and independent of this 
study. The causative mutation was mapped to a defined region around 100 Mb on 
chromosome 11. In the present study, the gene Gsdma3 (Table 3.8) was chosen 
for the sequence analysis as alopecia is described for Gsdma3 mutant phenotype 
(http://www.informatics.jax.org). 
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Table 3.8: Primer sequences of the candidate gene Gsdma3 (chr. 11, 98.4 Mb) of 
the line CLP001 
Primer Forward primer (5’-3’) Reverse primer (5’-3’)  Expected PCR product 
size (bp) 
E_1 tgatggatgcataaagcagc tgaggcctactataagtcc 278 
E_2 tctactctaggagtgaagcc agccccacagcatccttcagag 368 
E_3 agagctgggctctgaagg agatacttccaatctctacactgc 477 
E_4 cttggtgaagaaatgttgagg tgtctctctccatccctgtc 226 
E_5-6 ggttctcagagaattcacag gtaagttataggagctgctgc 735 
E_7 gaggctgtcttagcctatgg accatcttcccggtcagtcc 178 
E_8-9 tgaagcctacagaacctatg acagaaagaaactcgtctgac 848 
E_10-11 tgatcagagtgtgctaacac tatcctcagactggaggctc 725 
The position is given according to http://www.ensembl.org. 
3.3.4.2 Genotyping of the animals of line CLP001 
A novel missense point mutation in the gene Gsdma3 was identified as causative 
mutation in the line CLP001. No restriction enzyme site was affected due to the 
mutation. Therefore, genotyping of the animals of line CLP001 was done using 
the amplification refractory mutation system PCR (ARMS-PCR; Newton et al. 
1989). The concept of the ARMS-PCR is the selective amplification of the wild-
type allele and the mutant allele by allele-specific internal primers in which the 
first nucleotide at the 3’ end binds either the wild-type nucleotide or the mutant 
nucleotide. The insertion of an additional mismatch at the third nucleotide of the 
3’ end increases the primer specificity for the respective alleles. ARMS-PCR is 
preferentially performed in a single reaction (single tube allele-specific PCR). The 
allele-specific internal primers with their respective external primers amplify the 
specific PCR products. An additional common PCR product is also amplified 
because of the external primers (Zinovieva et al. 1996, and refs. therein). The 
allele-specific reverse primer INT1 (5’ tttctccaaggattttactaaaa 3’) and the forward 
primer EXT1 (5’ caaatgagcatatgaatgaatag 3’) for amplifying the wild-type allele, 
and the allele-specific forward primer INT2 (5’ ctaactgaagaacaactgaataa 3’) and 
the reverse primer EXT2 (5’ atgttcccacaagttctagcg 3’) for the amplification of the 
mutant allele, were designed (Fig. 3.4). The PCR conditions are given below. 
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Components of the PCR master mixture (1×)           Volume (μl)
Distilled H2O                              
10× PCR buffer      
dNTPs (2 mM)                             
MgCl2 (25 mM)    
Primer EXT1 (10 mM)     
Primer EXT2 (10 mM)                  
Primer INT1 (10 mM)      
Primer INT2 (10 mM)                      
Taq DNA Polymerase (10 U/μl)        
Genomic DNA (100 ng/μl)                         
14.5 
2.5 
2.5 
2.5 
0.1 
0.1 
0.2 
0.2 
0.3 
2.0
 
 
Fig. 3.4: Principle of the ARMS-PCR. Primer INT1 is specific for the wild-type allele, as the 
complementary base binds at the 3’ end and allows the amplification of the wild-type allele. 
Primer INT2 is specific for the mutant allele and leads to the amplification of the mutant allele. 
3.4 Molecular genetic methodologies 
3.4.1 Genomic DNA isolation and analysis 
Genomic DNA was isolated from mouse tail tips. Tail tips were incubated in 400 
• 94˚C        5 min 
• 94˚C        30 sec 
• 49˚C        55 sec 
• 72˚C        55 sec 
• 72˚C        20 min 
35× 
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μl master mixture (375 μl cutting buffer (2.5 ml 1 M Tris/HCl pH 7.5, 5 ml 0.5 M 
EDTA pH 8.0, 1 ml 5 M NaCl, 250 μl 1 M DTT, 127 μl Spermidine and add 
distilled H2O to make 50 ml), 20 μl 20% SDS, and 5 μl proteinase K) at 60˚C 
overnight. Digested samples were centrifuged at 13,000 rpm for 2 min and 
supernatant was transferred to a 1.5 ml tube (Eppendorf, Hamburg, Germany).  
DNA was precipitated by adding 400 μl 100% isopropanol. The DNA pellet was 
washed twice with 70% ethanol and air dried. Further on, the pellet was resolved 
in 10 mM Tris buffer pH 8.0 by incubating at 50˚C for 90 min. The genomic DNA 
concentration was determined using a Gene Quant Pro spectrophotometer 
(Amersham Biosciences, Freiburg, Germany) and the final concentration was 
adjusted to 100 ng/μl. 
3.4.2 RNA isolation and analysis 
RNA was isolated from kidney tissues using the TRIzol® reagent (Invitrogen, 
Darmstadt, Germany).  Both kidneys of phenotypically mutant mice and wild-type 
mice from the lines HST014, HST011, and HST015 were dissected from 3-to 4-
month-old mice and stored at -80˚C. One third of the kidney tissue was transferred 
into a 2 ml RNase-free reaction tube containing 1 ml TRIzol® Reagent. 
Subsequently, the tissue was homogenized using the Polytron PT 1200 E tissue 
homogenizer (Kinematica, Lucerne, Switzerland). The rotor was washed serially 
with distilled H2O, 0.2 N NaOH, and again with distilled H2O after each sample to 
avoid cross contamination. Homogenized tissues were incubated at room 
temperature for 10 min. 200 μl chloroform was added; the suspension was mixed 
and again incubated at room temperature for 10 min. The samples were 
centrifuged at 10,500 rpm at 4˚C for 15 min and the supernatant was transferred to 
a new tube. 500 μl isopropanol was added; the samples were mixed and again 
centrifuged at 10,500 rpm at 4˚C for 15 min. The RNA pellet was washed twice 
with 75% ethanol and air dried. The RNA pellet was resolved in RNase-free H2O 
and incubated at 55˚C for 10 min. RNA concentration was determined using the 
Gene Quant Pro spectrophotometer (Amersham Biosciences, Freiburg, Germany), 
and the final concentration was adjusted to 500 ng/μl. RNA quality was checked 
by formaldehyde gel electrophoresis. A 1.5% agarose gel (Bio & Sell, Nürnberg, 
Germany) of volume 150 ml was prepared containing 6 ml 25× MOPS and 7.5 ml 
formaldehyde. RNA samples for loading were prepared by mixing 2 µl RNA (500 
ng/µl), 5 µl denaturing buffer (750 µl formamide, 250 µl formaldehyde, 150 µl 
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25× MOPS, 116 µl 86% glycerol, 122 µl 0.25% bromphenol blue, 122 µl 0.25% 
xylene cyanol, 6 µl ethidium bromide), and 10 µl distilled H2O. The samples were 
incubated at 55˚C for 10 min and subsequently put on ice for 2 min. RNA samples 
were loaded on the agarose gel and run at 120 volts for 50 min using 1× MOPS as 
running buffer. The signal quality of the 28S and 18S ribosomal RNA was 
visualised under UV light (Gel documentation system, Bio-Rad, California, 
USA). 
3.4.3 First strand cDNA synthesis 
Five µl RNA (500 ng/µl) samples were mixed with 15 µl DNA digest mixture (5 
µl DNaseI (1 U/µl), 2 µl RNasin (100 U/µl), 2 µl 10× buffer, and 6 µl H2O) and 
incubated at 37˚C for 60 min for removing contaminant DNA. Enzymes were 
inactivated at 75˚C for 10 min. Purification of the RNA samples was carried out 
by washing with 150 µl PCIA (25 ml Tris saturated phenol, 24 ml chloroform, 
and 1 ml isoamyl alcohol). The samples were mixed with 15 µl 3 M NaOAc and 
400 µl ethanol and frozen at -80˚C for 30 min. The samples were centrifuged at 
13,000 rpm at 4˚C for 30 min and the resulting pellet was washed with 75% 
ethanol. The pellet was air dried and dissolved in 20 µl RNase-free H2O. First 
strand cDNA synthesis was carried out by incubating 11 µl DNaseI digested RNA 
mixed with 1 µl 50 µM cDNAvor (Fermentas, St. Leon-Rot, Germany) at 70˚C 
for 10 min, and subsequently on ice for 2 min. Further on, 7 µl reaction buffer (4 
µl 5× buffer, 1 µl 10 mM dNTP and 2 µl 100 mM DTT) was added to the samples 
and incubated at 42˚C for 5 min. After that, 1 µl superscript reverse transcriptase 
(SuperScript® II RT; Invitrogen, Darmstadt, Germany) was added and further 
incubation was carried out for 60 min. Enzymes were inactivated at 75˚C for 15 
min and samples were stored at -20˚C.  
3.4.4 PCR  
PCR was carried out with standard conditions (10× PCR buffer, 2 mM dNTPs, 25 
mM MgCl2, 10 mM primers  and 5 U Taq DNA polymerase) using the 
GeneAmp® PCR System 9700 Thermocycler (Applied Biosystem, California, 
USA). PCR conditions were optimized for the product lengths and the annealing 
temperature of the primers. After carrying out the amplification of the templates, 
PCR products were mixed with 2.5 μl 6× loading dye (Fermentas, St. Leon-Rot, 
Germany) and loaded on a 0.7% agarose gel stained with ethidium bromide 
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(Merck, Darmstadt, Germany). The gel electrophoresis (Biorad PowerPac 300, 
Bio-Rad, California, USA) was carried out at 80 volts for 45 min. The pUC mix 
marker 8 (Fermentas, St. Leon-Rot, Germany) was used as molecular weight 
marker. PCR products were visualised under UV light. 
3.4.5 Elution of the PCR products from the agarose gel 
Gel elution of the PCR products was carried out using the QIAEX II gel 
extraction kit (QIAGEN, Hilden, Germany). PCR product bands were excised 
from the gel with the scalpel under the UV light. Three volumes QX 1 buffer and 
10 μl QIAEX II buffer were added to the gel slice and incubated at 50˚C for 10 
min for solubilizing the gel. Solubilized samples were centrifuged at 13,000 rpm 
for 30 sec. Further washing of the pellet was carried out with 500 μl QX 1 and 
subsequently with 500 μl PE buffer. The pellet was air dried and dissolved in 20 
μl 10 mM Tris buffer pH 8.0 for eluting the PCR product. The samples were 
centrifuged at 13,000 rpm for 30 sec and the supernatant containing the PCR 
products was transferred in a new tube. The concentration of the gel eluted PCR 
products was determined using a 0.7% agarose gel with a1 kb molecular marker. 
3.4.6 Sequencing of purified PCR products 
Sequencing of purified PCR products was performed in collaboration with the 
sequencing service of the Helmholtz Zentrum München. The purified PCR 
products were diluted as per formula (DNA amount in ng = length in bp/100 × 
1.5). Two μl of the purified PCR products was mixed with the sequencing master 
mixture (4 μl 5× sequencing buffer, 1 μl terminator big dye (Applied Biosystem, 
California, USA), 1 μl primer, and 2 μl H2O). The sequencing PCR conditions are 
described below.  
 
• 95˚C         1 min 
• 95˚C          5 sec 
• 50˚C        10 sec 
• 60˚C         4 min    
40× 
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The sequencing samples were purified by ethanol precipitation. Samples were 
mixed with 2.5 μl 125 mM EDTA and 30 μl 100% ethanol and put on ice for 15 
min. After that, samples were centrifuged at 13,000 rpm at 4˚C for 30 min. The 
pellet was washed with 70% ethanol and air dried. The pellet was dissolved in 30 
μl distilled H2O and transferred to the sequencing plate. Sequencing of the 
samples was carried in collaboration with the Helmholtz Zentrum München.  
3.5 Phenotype analysis 
3.5.1 Blood plasma analysis 
Blood samples were collected by puncturing the retro orbital sinus under ether 
anaesthesia using Na-heparin treated glass capillaries (Hirschmann Laborgeraete, 
Eberstadt, Germany) in 1 ml lithium-heparin treated tubes (Kabe Labortechnik, 
Nümbrecht-Elsenroth, Germany) for the clinical chemical analysis of the blood 
plasma. Plasma samples were prepared by centrifuging the blood at 7,000 rpm for 
10 min. Approximately 150 µl plasma was collected. The plasma parameters were 
measured in collaboration with the clinical chemical screen (Dr. B. Rathkolb, 
Chair for Molecular Animal Breeding and Biotechnology, LMU München) within 
the German Mouse Clinic (Prof. Dr. M. Hrabé de Angelis) of the Helmholtz 
Zentrum München (see Table 2.6). An Olympus AU400 autoanalyzer (Olympus, 
Hamburg, Germany) was used with the respective kits. Plasma creatinine was 
determined using two different methods, Jaffe’s kinetic method (OSR6178, 
Beckman Coulter, California, USA; creatinine-J) and the enzymatic method 
(OSR61204, Beckman Coulter, California, USA; creatinine-E). 
3.5.2 Metabolic cage analysis 
Phenotypically mutant mice of the lines HST014 and HST011 exhibited increased 
plasma urea values as compared to wild-type littermate controls. Therefore, 
analysis of the renal function of phenotypically mutant mice of both lines was 
carried out using metabolic cages (Tecniplast, Hohenpeissenberg, Germany). At 
the age of 14 weeks, phenotypically mutant animals and wild-type littermate 
controls were separated in single metabolic cages for 1-2 h for 3 consecutive days 
for habituation providing crushed food and water ad libitum. On day 4 (0 h), the 
metabolic cages were cleaned. Body weight, food weight, and water weight were 
measured before the mice were put in the cages. Urine was collected for 24 h and 
stored at -20˚C, and parameters (body weight, 24 h water intake, 24 food intake, 
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24 h urine volume, and 24 h faeces excretion) were measured, and the mice were 
again provided with fresh water and food. After 24 h (48 h from 0 h), all 
parameters stated above were measured again, and the metabolic cages were 
cleaned. For the next 24 h, the mice were kept under water deprivation, and all 
parameters were measured. To avoid urine evaporation, 1 ml paraffin was added 
in the urine collecting tubes. Urine samples were stored at -80˚C for further 
analysis. The clinical chemical analysis of blood and urine was performed in 
collaboration with the clinical chemical screen (Dr. B. Rathkolb, Chair for 
Molecular Animal Breeding and Biotechnology, LMU München) within the 
German Mouse Clinic (Prof. Dr. M. Hrabé de Angelis) of the Helmholtz Zentrum 
München. 
3.5.3 Morphological studies 
Three-to four-month-old phenotypically mutant animals and sex-matched control 
animals of the lines HST014, HST011, and CLP001 were analyzed for growth 
parameters. Body weight was measured before euthanasia. Mice were euthanized 
by bleeding from the retro-orbital sinus under ether anaesthesia followed by 
cervical dislocation for the determination of the organ weights. Nose-to-rump 
length was measured in dorsal position. The organs were dissected, blotted on 
tissue paper to dry, and weighed to the nearest 0.1 mg. The organs kidney, liver, 
spleen, urinary bladder, testis/uterus, lung, heart and brain were weighed. Carcass 
weight was measured with skin and body fat. Tail samples were collected for 
genotype analysis and stored at -20˚C. For the lines HST014 and HST011, both 
kidneys were stored in 4% paraformaldehyde. Histopathological studies were 
carried out at the Institute of Veterinary Pathology (Prof. Dr. R. Wanke), LMU 
München. In line CLP001, the course of hair loss was also assessed.  
3.5.4 SDS-PAGE analysis for the detection of albuminuria 
Examination of albuminuria in mutant lines with renal disorder was carried out by 
the qualitative analysis of urinary proteins using SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). 20 μl spot urine samples or collected in the 
metabolic cage were taken from 3-to 4-month-old mice and stored at -20˚C. For 
SDS-PAGE analysis, urine samples were boiled for 10 min after 1:2 dilutions 
with sample buffer (62.5 mM Tris-HCl pH 6.8, 2% SDS, 25% glycerol, 0.01% 
bromophenol blue, 5% 2-mercaptoethanol). 10 μl of the samples were 
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electrophoresed (25 mM Tris, 200 mM glycine, 0.1% SDS) in a 10% Tris-HCl-
polyacrylamide gel using the Bio-Rad Mini Protean II system (Bio-Rad 
Laboratories, California, USA). Protein bands were visualized by staining with 
Coomassie Brilliant Blue dye. The prestained SDS-PAGE Standard Broad 
(catalog: 161-0318; Bio-Rad Laboratories, California, USA) was used as 
molecular weight standard for the detected bands. Wild-type littermates were used 
as controls.  
3.5.5 Generation of a congenic line 
Congenic lines harbour the mutant allele on different genetic backgrounds and 
therefore, they are used to study the mutant phenotype of a given allele on 
different genetic backgrounds (Silver 1995). After carrying out 10 backcrosses, a 
congenic line harbouring more than 99% genome of the recipient strain is 
established. After identification of the causative mutations in the lines HST014 
and HST011, establishment of congenic lines on the C57BL/6 and BALB/c inbred 
genetic backgrounds was started. Therefore heterozygous mutant mice on the 
C3H genetic background were bred to the recipient strain. The offspring were 
genotyped by PCR-RFLP, and heterozygous mutant mice were again bred with 
the recipient strain. In line HST015, phenotypically heterozygous mutant 
backcross mice were used for breeding. 
3.6 Data presentation and statistical analysis of the data 
Data are presented as means ± standard deviation (SD). Data charts were plotted 
with GraphPad Prism 5.0 (GraphPad Software, California USA). Data were 
analyzed using the Student’s t-test and p values <0.05, <0.01 and <0.001 were 
considered to be significant. 
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IV. RESULTS 
4.1 Line HST014 
4.1.1 Linkage analysis of the causative mutation  
After having carried out matings of phenotypically heterozygous mutant mice of 
line HST014 with the genetic background of the C3H inbred strain to inbred 
BALB/c mice for two generations, the complete penetrance of the mutant 
phenotype (increased plasma urea levels) was observed in the backcross animals 
in both sexes (Table 4.1) as expected by the rules of Mendelian inheritance. 
Linkage analysis was carried out with 113 SNPs using 45 phenotypically mutant 
G2 animals in collaboration with the Institute of Experimental Genetics (Prof. Dr. 
M. Hrabé de Angelis), Helmholtz Zentrum München (Table 4.2). The analysis 
showed that the mutant phenotype is linked to chromosome 18.  
Table 4.1: Total number of backcross animals of line HST014 
Generation Total (m/f) Phenotypically 
mutant (m/f) 
Phenotypically wild-
type (m/f) 
G1 49 (28/21) 24 (14/10) 25 (14/11) 
G1 (%)  49% 51% 
G2 296 (152/144) 145 (73/72) 151 (79/72) 
G2 (%)  49% 51% 
m: males; f: females. 
Table 4.2: Genetic mapping of phenotypically mutant G2 backcross animals of 
line HST014 
Chromosome rSNP Locus 
(Mb) 
Num_het Num_wt Failed Total χ2 
value 
P value 
1 rs13475764 23.5 28 16 1 45 N.S. >0.01 
1 rs13475818 38.1 27 14 4 45 N.S >0.01 
1 rs32716288 65.6 31 14 0 45 N.S. >0.01 
1 rs3678148 76.2 30 15 0 45 N.S >0.01 
1 rs13476065 116.7 26 19 0 45 N.S. >0.01 
1 rs30551255 126.9 21 18 6 45 N.S >0.01 
1 rs30942489 144.1 26 19 0 45 N.S. >0.01 
1 rs31593281 159.9 25 20 0 45 N.S >0.01 
1 rs33777727 172.7 25 20 0 45 N.S. >0.01 
1 rs13499691 195.1 29 16 0 45 N.S >0.01 
2 rs13476355 14.3 28 17 0 45 N.S. >0.01 
2 rs27120459 20.2 25 18 2 45 N.S >0.01 
2 rs13476434 37.0 27 16 2 45 N.S. >0.01 
2 rs13476490 50.7 23 19 3 45 N.S >0.01 
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2 rs13476567 70.8 22 23 0 45 N.S. >0.01 
2 rs3679193 95.6 18 21 6 45 N.S >0.01 
2 rs27441842 114.2 21 24 0 45 N.S. >0.01 
2 rs27257388 129.5 21 24 0 45 N.S >0.01 
2 rs3696248 164.2 20 25 0 45 N.S. >0.01 
2 r13476909 169.3 19 26 0 45 N.S >0.01 
2 rs3691120 181.6 17 27 1 45 N.S. >0.01 
3 rs13477026 26.3 25 20 0 45 N.S >0.01 
3 rs3151604 36.9 22 22 1 45 N.S. >0.01 
3 rs3685081 52.2 25 20 0 45 N.S >0.01 
3 rs13477178 69.6 25 20 0 45 N.S. >0.01 
3 rs8259135 89.0 21 24 0 45 N.S >0.01 
3 rs13477302 103.3 21 24 0 45 N.S. >0.01 
3 rs13477321 109.0 25 20 0 45 N.S >0.01 
3 rs16799508 129.6 25 19 1 45 N.S. >0.01 
4 rs27731305 10.9 27 17 1 45 N.S >0.01 
4 rs27781503 35.2 27 18 0 45 N.S >0.01 
4 rs28056583 86.8 24 21 0 45 N.S. >0.01 
4 rs28307021 101.2 21 24 0 45 N.S >0.01 
4 rs13477989 133.1 20 25 0 45 N.S. >0.01 
4 rs3711383 141.9 18 26 1 45 N.S >0.01 
5 rs13481347 14.0 21 24 0 45 N.S. >0.01 
5 rs13478148 24.9 21 24 0 45 N.S >0.01 
5 rs13478204 41.0 20 24 1 45 N.S. >0.01 
5 rs13478263 55.6 21 24 0 45 N.S >0.01 
5 rs29635956 67.9 22 23 0 45 N.S. >0.01 
5 rs31585424 79.4 23 22 0 45 N.S >0.01 
5 rs31610566 81.9 19 20 6 45 N.S. >0.01 
5 rs13478429 103.3 25 20 0 45 N.S >0.01 
5 rs32067291 111.7 24 21 0 45 N.S. >0.01 
5 rs13478514 127.2 23 22 0 45 N.S >0.01 
6 rs13478670 26.1 24 20 1 45 N.S. >0.01 
6 rs13478756 52.7 23 20 0 45 N.S >0.01 
6 rs13478816 72.3 22 23 0 45 N.S. >0.01 
6 rs13478872 85.9 21 20 4 45 N.S >0.01 
6 rs13478987 115.2 25 20 0 45 N.S. >0.01 
6 rs16815348 137.6 27 18 0 45 N.S >0.01 
6 rs13479084 144.5 25 19 1 45 N.S. >0.01 
7 rs13479164 28.1 19 26 0 45 N.S >0.01 
7 rs13479256 60.7 14 31 0 45 N.S. >0.01 
7 rs16805799 73.2 13 31 1 45 N.S >0.01 
7 rs4226783 100.1 15 30 0 45 N.S. >0.01 
7 rs13479476 124.0 19 26 0 45 N.S >0.01 
8 rs13479604 9.8 21 24 0 45 N.S. >0.01 
8 rs13479662 28.1 20 22 3 45 N.S >0.01 
8 rs13479741 48.2 26 19 0 45 N.S. >0.01 
8 rs13479814 70.9 24 21 0 45 N.S >0.01 
8 rs13479998 116.7 20 25 0 45 N.S. >0.01 
9 rs13480217 57.7 26 16 3 45 N.S >0.01 
9 rs13480245 65.0 26 19 0 45 N.S. >0.01 
9 rs3673055 96.2 44 1 0 45 N.S >0.01 
10 rs13480484 8.2 19 26 0 45 N.S. >0.01 
10 rs13480541 22.6 18 27 0 45 N.S >0.01 
10 rs13480638 68.9 26 19 0 45 N.S. >0.01 
10 rs8258500 99.5 26 19 0 45 N.S >0.01 
10 rs13480784 117.8 26 17 2 45 N.S. >0.01 
11 rs13480851 7.1 20 22 3 45 N.S >0.01 
11 rs13480905 21.6 24 21 0 45 N.S. >0.01 
11 rs26822879 32.3 24 21 0 45 N.S >0.01 
11 rs26982471 53.9 22 23 0 45 N.S. >0.01 
11 rs13481061 62.8 22 22 1 45 N.S >0.01 
11 rs13481127 83.2 19 26 0 45 N.S. >0.01 
11 rs27041242 98.6 21 24 0 45 N.S >0.01 
11 rs27000576 114.3 20 23 2 45 N.S. >0.01 
12 rs13481307 13.2 16 29 0 45 N.S >0.01 
12 rs13481351 25.7 0 44 1 45 N.S. >0.01 
12 rs8259450 75.0 17 23 5 45 N.S >0.01 
12 rs6194112 83.4 22 22 1 45 N.S. >0.01 
12 rs13481604 99.3 22 22 1 45 N.S >0.01 
12 rs13459138 114.1 24 21 0 45 N.S. >0.01 
13 rs6345767 19.5 20 25 0 45 N.S >0.01 
13 rs13481783 42.9 25 20 0 45 N.S. >0.01 
13 rs13481863 69.3 27 18 0 45 N.S >0.01 
13 rs13481910 83.1 26 19 0 45 N.S. >0.01 
13 rs29566800 97.2 26 18 1 45 N.S >0.01 
13 rs30511458 111.2 27 18 0 45 N.S. >0.01 
14 rs30406796 22.9 17 28 0 45 N.S >0.01 
14 rs30895903 59.6 25 20 0 45 N.S. >0.01 
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14 rs30865397 74.0 26 19 0 45 N.S >0.01 
15 rs13482484 25.2 19 26 0 45 N.S. >0.01 
15 rs13482528 38.8 20 25 0 45 N.S >0.01 
15 rs13482574 50.4 19 25 1 45 N.S. >0.01 
15 rs16820334 85.6 23 22 0 45 N.S >0.01 
15 rs16804751 97.7 25 17 3 45 N.S. >0.01 
16 rs4161352 10.8 16 29 0 45 N.S >0.01 
16 rs4165602 27.4 16 28 1 45 N.S. >0.01 
16 rs4170048 32.1 17 26 2 45 N.S >0.01 
17 rs33418817 11.5 27 17 1 45 N.S. >0.01 
17 rs33259283 28.1 27 18 0 45 N.S >0.01 
17 rs33428427 40.9 27 18 0 45 N.S. >0.01 
17 rs13483097 72.7 24 21 0 45 N.S >0.01 
17 rs13483140 85.4 21 24 0 45 N.S. >0.01 
18 rs29827614 25.5 38 7 0 45 21.3 <0.0001 
18 rs29823686 38.2 37 8 0 45 18.6 <0.001 
18 rs13483427 70.6 31 14 0 45 6.42 <0.01 
19 rs6247194 13.9 26 19 0 45 N.S >0.01 
19 rs13483576 26.0 22 23 0 45 N.S. >0.01 
19 rs4232188 43.5 21 24 0 45 N.S >0.01 
19 rs6339594 56.3 19 26 0 45 N.S. >0.01 
Num_het: number of mice with heterozygous C3H/BALB/c genotype; Num_wt: number of mice 
with homozygous wild-type BALB/c/BALB/c genotype; N.S: non-significant. SNPs refer to the 
NCBI database (http://www.ncbi.nlm.nih.gov/) 
Further fine mapping of the causative mutation was carried out using SNP 
markers (rs52303422: 9.5 Mb; rs52534573: 11.2 Mb; rs46961948: 11.4 Mb; 
rs52391350: 12.9 Mb; rs52376653: 13.6 Mb; rs31073798: 14.3 Mb; rs31158307: 
14.6 Mb; rs31155567: 14.6 Mb; rs31158391: 14.6 Mb; rs31243033: 17.0 Mb; 
rs31247952: 17.0 Mb; rs31220775: 17.5 Mb; rs51268966: 23.4 Mb; rs52585890: 
26.1 Mb) and the microsatellite markers D18Mit68 (C3H: 113 bp; BALB/c: 95 
bp) (Fig. 4.1) and D18Mit70 (C3H: 124 bp; BALB/c: 108 bp) (Table 4.3). 
Although the SNPs were published to detect polymorphic alleles in C3H and 
BALB/c mice, in this study no allelic difference was seen in C3H and BALB/c 
mice. From the polymorphic markers used for chromosome 18, rs29827614 and 
D18Mit68 showed the highest χ2 value (Tables 4.2 and 4.3). 
 
Fig. 4.1: Electrophoretic pattern of the C3H (113 bp) and BALB/c (95 bp) allele amplified using 
polymorphic marker D18Mit68. Lanes 1-15 are backcross animals. Lanes 3, 8, and 12 show 
animals which are homozygous for the BALB/c allele, the other mice show a heterozygous 
C3H/BALB/c genotype. Lane M is the pUC 8 marker. 
 1    2       3      4      5       6       7     M     8     9     10    11     12     13    14      15 
113 bp  
95 bp 
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Table 4.3: Fine mapping analysis of chromosome 18 in line HST014 
Marker Locus (Mb) Num_het Num_wt Failed Total χ2 value 
D18Mit68 21.5 38 7 0 45 21.4 
D18Mit70 35.0 35 10 0 45 12.3 
Num_het: number of mice with heterozygous C3H/BALB/c genotype; Num_wt: number of mice 
with homozygous wild-type BALB/c/BALB/c genotype. 
4.1.2 Identification of the causative mutation 
The three candidate genes Aqp4, Mep1b, and Kctd1 were chosen for sequence 
analysis (Table 4.4). Two phenotypically heterozygous mutant mice and two wild-
type mice on the C3H genetic background were used. Genomic DNA and RNA 
were prepared from tails and kidneys, respectively, and cDNA was prepared from 
RNA to use as template in the PCR reaction. For Aqp4, exonic sequences as well 
as 3’ UTR and 5’ UTR regions were sequenced, whereas for Kctd1 and Mep1b, 
cDNA transcripts were sequenced (Fig. 4.2).  
Table 4.4: Candidate genes in line HST014 and their published phenotype data 
Gene Position 
(Mb) 
Exons Polypeptide length (aa) Mutant phenotype 
(http://www.informatics.jax.org/) 
Aqp4 15.5 5 323 Homozygous knockout mice 
exhibited decreased urine osmolality 
associated with reduced water 
permeability in inner medullary 
collecting ducts, increased survival 
rates and reduced brain edema after 
acute water intoxication and 
ischemic stroke, as well as 
significant hearing impairment 
(Kitaura et al. 2009, Ma et al. 1997). 
Mep1b 21.2 15 704 Homozygous knockout mice 
showed 50% prenatal lethality; 
survivors had reduced birth weight 
and showed altered renal gene 
expression (Norman et al. 2003). 
Kctd1 15.1 5 265 No mutant phenotype is published 
(http://www.informatics.jax.org/). 
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A) 
 
B) 
 
C) 
 
Fig. 4.2: Position and length of PCR products amplified on the candidate genes of line HST014. 
A) Kctd1 cDNA. B) Aqp4 gene. C) Mep1b cDNA. E: exon 
Sequence analysis of Aqp4 and Mep1b resulted in identical sequences in wild-type 
and phenotypically heterozygous mutant animals, which were also identical to the 
published sequences in the Ensembl database (http://www.ensembl.org/). 
Sequence analysis of the Kctd1 cDNA transcript revealed a point mutation 
resulting in a T→A transversion at nt 80 (ENSMUST00000025992, as of March 
2011), which leads to the amino acid exchange from isoleucine to asparagine at aa 
position 27 (Fig. 4.3). The name of line HST014 was designated as Kctd1I27N. 
 
2.2 kb 
 
612 bp 
540 bp 
660 bp 
660 bp 
E1  E2  E3  E4   E5      E6        E7               E8        E9           E10                    E11            E12     E13        E14      E15
861 bp 
E1     E2              E3            E4                            E5 
1.7 kb 
14.3 kb 
305 bp 337 bp 550 bp 257 bp 402 bp 
   E1                             E2                         E3                       E4                                                         E5  
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Fig. 4.3: Electropherogram of the sequence of the gene Kctd1. Sequence from A) a phenotypically 
wild-type mouse, B) a phenotypically heterozygous mutant mouse, and C) a homozygous mutant 
fetus (see 4.1.4). The arrow shows the position of the T to A transversion which leads to the amino 
acid exchange from isoleucine to asparagine at aa position 27. 
4.1.3 Allelic differentiation of the Kctd1I27N mutation by PCR-RFLP 
The point mutation abolished the restriction site for the enzyme BsmI. Thus, PCR 
products (520 bp) encompassing the mutation site amplified from the mutant 
allele remain unrestricted, whereas PCR products of the wild-type allele were 
restricted in two fragments (312 bp and 208 bp). Restricted fragments were 
analyzed on a 2% agarose gel (Fig. 4.4).  
 
Fig. 4.4: Electrophoretic pattern of the PCR–RFLP in the line Kctd1I27N. Lanes 2, 4, 5, 6, 7, and 9: 
phenotypically heterozygous mutant mice; lanes 3 and 8: phenotypically wild-type mice. Lane M 
is the pUC 8 marker. 
4.1.4 Analysis of Kctd1I27N homozygous mutant mice  
To assess the consequences of homozygosity of the mutation, Kctd1I27N 
heterozygous mutant mice were intercrossed to generate homozygous mutant 
animals. At three months of age, 47 offspring from four mating pairs were 
analyzed (Table 4.5). We did not find any homozygous mutant mice whereas 
heterozygous mutant mice (n = 31) and wild-type mice (n = 16) appeared in a 2:1 
ratio as expected. Next, we carried out timed matings of heterozygous mutant 
mice to harvest fetuses at day E17.5 for the analysis. A total of 21 fetuses were 
  M        2          3        4           5         6          7          8          9       M 
520 bp 
 
312 bp 
208 bp 
                A                                         B                           C 
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harvested from three matings and all appeared grossly normal in their 
morphology. Homozygous mutant, heterozygous mutant, and wild-type animals 
were observed according to the Mendelian ratio in the genotype analysis (Table 
4.5, Fig. 4.5). Hence, homozygous mutant mice showed early postnatal mortality. 
Table 4.5: Number of offspring produced from matings of Kctd1I27N heterozygous 
mutant mice of line Kctd1I27N 
Time of analysis Total  Genotype  
  Homozygous 
mutant 
Heterozygous 
mutant 
Wild-type 
3 months  47 0 (0%) 31 (66%) 16 (34%) 
Fetal (E17.5) 21 5 (24%) 10 (48%) 6 (28%) 
 
 
Fig. 4.5: Electrophoretic pattern of the PCR-RFLP in the line Kctd1I27N using fetuses (E17.5). Lane 
1: heterozygous mutant; lanes 2, 3, 4: wild-type; and lane 5: homozygous mutant. Lane M is the 
pUC 8 marker.  
4.1.5 Clinical chemical analysis of Kctd1I27N heterozygous mutant mice  
The mutant line HST014 was established due to increased plasma urea levels in 
heterozygous mutant mice. Therefore, heterozygous mutant mice on the C3H 
genetic background were mated with wild-type C3H mice and heterozygous 
mutant offspring were used for clinical chemical analysis compared to wild-type 
littermates. At the age of three months, heterozygous mutant animals of both 
genders showed significantly increased levels of urea, creatinine-J, potassium, α-
amylase, and lipase in the blood plasma. Heterozygous mutant females showed 
hypercalcemia (Table 4.6). Plasma urea was already found to be increased at 6 
and 9 weeks of age in both sexes (Fig. 4.6). 
 
520 bp 
312 bp 
208 bp 
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Fig: 4.6: Plasma urea level in females at different ages. wt: wild-type; het: heterozygous mutant; 
wks: weeks. CStudent’s t-test vs wild-type: p<0.001. Data represents mean ± SD. 10-26 mice are 
analyzed per genotype. 
4.1.6 Urine analysis of Kctd1I27N heterozygous mutant mice  
Metabolic cage analysis was carried out with heterozygous mutant mice and age-
matched wild-type littermate controls at the age of 14-15 weeks. Heterozygous 
mutant males showed a significant increase in water intake and mild polyuria as 
well as distinct hypercalciuria. Heterozygous mutant females also showed distinct 
hypercalciuria as well as a moderate increase in water intake and urine volume. 
Creatinine excretion measured with the enzymatic method (creatinine-E) was 
significantly reduced in heterozygous mutant females. After 24 h water 
deprivation, heterozygous mutant mice showed no significant differences (Table 
4.7). 
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4.1.7 Morphological analysis of Kctd1I27N heterozygous mutant mice 
Morphological analysis including determination of body and organ weights was 
performed on four month old Kctd1I27N heterozygous mutants of both sexes and 
wild-type littermates as controls. Heterozygous mutants of both sexes were viable 
and fertile, and no grossly apparent phenotype was observed. Heterozygous 
mutant females showed a decreased body weight and kidney weight. However, 
the relative kidney weight was unaltered. Further, the relative brain weight was 
increased in the heterozygous mutant females. The absolute (Table 4.8) and 
relative weights of the other organs (data not shown) of heterozygous mutants of 
both genders were not significantly altered. Kidneys from heterozygous mutants 
were light microscopically indistinguishable from those of wild-type littermates 
(not shown). 
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4.2 Line HST011 
4.2.1 Re-analysis of line HST011 showed erroneous linkage analysis 
Line HST011 was established in the screen for recessive mutations within the 
Munich ENU mouse mutagenesis project. Phenotypically homozygous mutant 
animals showed increased plasma urea levels with small kidneys. Linkage 
analysis was already carried out previously, independent from this study (see 
3.1.2). Genetic analysis revealed linkage of the causative mutation to chromosome 
7 (χ2 = 15.5) and chromosome 1 (χ2 = 9.9; Table 4.9).  
Table 4.9: Data from the previous linkage analysis of line HST011 carried out 
independently from this study 
Chromosome rSNP Locus 
(Mb) 
Num_hom Num_het Num_wt Total χ2 
value 
P value 
1 rs13475764 23.5 21 16 10 47 9.9 >0.001 
1 rs13475818 38.1 21 16 10 47 9.9 >0.001 
7 rs4226783 100.0 20 23 4 47 10.9 >0.001 
7 rs13479476 124.0 22 22 3 47 15.5 >0.0001 
Num_hom: number of mice with homozygous C3H/C3H genotype; num_het: number of mice with 
heterozygous C3H/BALB/c genotype; num_wt: number of mice with homozygous 
BALB/c/BALB/c genotype. 
Based on these results, analysis of line HST011 in this study started with the fine 
mapping of the causative mutation. As the highest linkage was revealed for 
chromosome 7, additional polymorphic markers were examined for the defined 
region (Table 4.10). However, no clear linkage of the causative mutation was 
observed. 
Table 4.10: Polymorphic markers used for fine mapping in line HST011 
Marker Locus (Mb) Num_hom Num_het Num_wt Failed Total 
D7Mit90 87.5 11 28 5  0 44 
D7Mit323 108.0 18 18  8  0 44 
D7Mit68 132.4 22  19 3  0 44 
D7Mit259 151.9 16  21  7  0 44 
Num_hom: number of mice with homozygous C3H/C3H genotype; num_het: number of mice with heterozygous 
C3H/BALB/c genotype; num_wt: number of mice with homozygous BALB/c/BALB/c genotype. 
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Simultaneously, based on mutant phenotype and linked chromosomal region, 
three candidate genes were selected for sequence analysis (Table 4.11). Two 
phenotypically homozygous mutant animals and two wild-type animals on the 
C3H genetic background were used. Genomic DNA and RNA were prepared from 
tail and kidney, respectively, and cDNA was prepared from RNA for cDNA 
sequencing. For Umod, cDNA and 5’ UTR were sequenced, and for Aqp11 and 
Wnt11 exonic sequences were analyzed. Sequences of all three genes were 
identical in phenotypically mutant animals and wild-type animals. 
Table 4.11: Candidate genes for line HST011 on chromosome 7 
Gene Position 
(Mb) 
Exons Polypeptide length (aa) Mutant phenotype 
(http://www.informatics.jax.org/) 
Umod 126.6 11 642 Knock-out homozygous mutant 
mice exhibited increased 
susceptibility to bladder infection 
and abnormal kidney function. 
ENU-induced homozygous mutants 
exhibited abnormal kidney function 
and decreased metabolic rate, body 
weight, and bone density (Bates et 
al. 2004, Kemter et al. 2009, Mo et 
al. 2004). 
Wnt11 105.9 7 354 Knock-out homozygous mutants 
showed high embryonic lethality, 
and born mutants died within the 
first 2 days. The kidneys were small 
and exhibited delayed development 
(Majumdar et al. 2003). 
Aqp11 104.8 3 271 Homozygous mutant mice displayed 
premature death, kidney failure, and 
polycystic kidneys with cysts 
originating from the proximal 
tubules, and growth retardation 
(Morishita et al. 2005). 
 
After that, the breeding data of the backcross animals used in the previous linkage 
analysis was re-analyzed. It was revealed that more phenotypically mutant G2 
animals appeared than expected according to the Mendelian ratio (Table 4.12). It 
was assumed that an erroneous mating during the backcross breeding might have 
been occurred. In the mouse facility, additional ENU-induced mutant lines 
exhibiting increased plasma urea levels were maintained including the UmodC93F 
mutant line with the causative mutation found on chromosome 7 (Prückl 2011). 
Therefore, the G2 backcross animals were genotyped for this point mutation by 
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using allele-specific PCR strategy. Some backcross animals were found with the 
UmodC93F mutant allele (Fig 4.7). This clearly showed that a mutant mouse from 
the UmodC93F mutant line was erroneously used for the backcross mating of line 
HST011.  
The subsequent analysis of the original line HST011 on the C3H genetic 
background did not reveal the UmodC93F mutant allele in these mice. 
Table 4.12: Observed phenotype of the 276 G2 backcross animals of line HST011  
 Phenotypically homozygous 
mutant 
Phenotypically  wild-type 
(heterozygous mutant and 
wild-type) 
Number of G2 backcross 
animals (%) 
121 (44%) 155 (56%) 
Expected phenotype ratio 25% 75% 
 
 
Fig. 4.7: Allele-specific PCR for the UmodC93F mutation. Samples from eight G2 backcross 
animals of line HST011 are shown. Lanes 1-8 WT show the result for the wild-type allele (171 bp) 
whereas lanes 1-8 Mut show the result for the mutant allele (321 bp). The samples 1-5 are 
homozygous wild-type and samples 6, 7 and 8 are heterozygous for the UmodC93F mutation. Lane 
M is the pUC8 marker.  
4.2.2 Re-mapping of the causative mutation to chromosome 1 
The phenotypically mutant G2 animals were screened for the UmodC93F mutation. 
Animals carrying the mutant allele were excluded from the analysis. Linkage 
analysis with this reduced pool of phenotypically mutant G2 animals showed a 
strong linkage of the causative mutation to a single locus on chromosome 1 
(analogous to the data shown in Table 4.12). Therefore, fine mapping was carried 
out with phenotypically mutant G2 animals using additional polymorphic markers 
for chromosome 1 (Table 4.13).  
                    WT                                                 Mut  
  1   2   3    4     5    6    7    8    M   1    2    3     4     5     6    7     8   M 
321 bp 
171 bp 
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Table 4.13: Polymorphic markers of chromosome 1 used for fine mapping 
Marker Locus (Mb) Num_hom Num_het Num_wt Failed Total 
D1Mit64 12.8 14  8 0  0  22 
D1Mit432 24.3 12  4 4  4  24 
D1Mit411 33.2 10  6 8  0  24 
D1Mit212 40.0 17  4 1  0  22 
D1Mit156 65.8 9  13 6  0  28 
D1Mit415 88.3 9  12 6  1  28 
Num_hom: number of mice with homozygous C3H/C3H genotype; num_het: number of mice with 
heterozygous C3H/BALB/c genotype; num_wt: number of mice with homozygous 
BALB/c/BALB/c genotype. 
Phenotypically homozygous mutant G2 animals should have the homozygous 
C3H/C3H genotype at the chromosomal site of the causative mutation. The 
highest number of animals having a homozygous C3H/C3H genotype were found 
at 40.0 Mb, and it was revealed with marker D1Mit212 (Fig. 4.8).  
 
Fig. 4.8: Electrophoretic pattern of the C3H and BALB/c allele amplified by marker D1Mit212.  
Lane 1: wild-type C3H; lane 2: wild-type BALB/c; lanes 3-8: phenotypically homozygous mutant 
G2 mice. Lane M is the pUC8 marker. 
4.2.3 Sequence analysis of the gene Pou3f3  
The candidate gene Pou3f3 was selected for the sequence analysis, as it is located 
at 42.7 Mb on chromosome 1, and a published mutant phenotype has been 
described with increased plasma urea and potassium levels associated with renal 
hypoplasia (http://www.informatics.jax.org/). Pou3f3 consists of a single exon 
(3062 bp) which codes for a 497 aa polypeptide (Fig. 4.9).  
 
C3H (214 bp) 
BALB/c (149 bp) 
 M        1           2           3             4         5           6            7           8       M 
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Fig. 4.9: Position and length of PCR products amplified on the candidate gene Pou3f3 of line 
HST011. E: exon 
Two phenotypically homozygous mutant mice and two wild-type mice were 
analyzed for the exonic sequence. Sequence analysis revealed a T→C point 
mutation at nt 1268 (ENSMUST00000054883, Fig. 4.10). The resulting causative 
mutation leads to the amino acid exchange from leucine to proline at aa position 
423. The name of line HST011 was designated as Pou3f3L423P. 
 
Fig. 4.10: Electropherogram of the sequence of the gene Pou3f3. Sequence from A) a 
phenotypically wild-type mouse, B) a heterozygous mutant mouse, and C) a phenotypically 
homozygous mutant mouse. The arrow shows the position of the T to C transition which leads to 
the amino acid exchange from leucine to proline at aa position 423. 
4.2.4 Allelic differentiation of the Pou3f3L423P mutation by PCR-RFLP 
The point mutation in the Pou3f3L423P mutant line abolished the restriction site for 
the enzyme SmlI. Therefore, PCR products (460 bp) derived from the wild-type 
allele were restricted into two fragments (353 bp and 107 bp), whereas PCR 
products amplified from the mutant allele remained unrestricted. SmlI digested 
PCR products were analyzed on a 2% agarose gel electrophoresis (Fig. 4.11).  
                  A                                                 B                                                            C 
682 bp 
3.06 kb 
 E1 
560 bp 658 bp 
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Fig. 4.11: Electrophoretic pattern of the PCR–RFLP in the line Pou3f3L423P. Lane 1: 
phenotypically homozygous mutant mouse; lanes 2 and 3: heterozygous mutant mice; lane 4: wild-
type mice. Lane M is the pUC 8 marker. 
4.2.5 Clinical chemical analysis of Pou3f3L423P homozygous mutant mice 
The recessive mutant line HST011 was established due to increased plasma urea 
levels in homozygous mutant mice. Heterozygous mutant mice on the C3H 
genetic background were intercrossed to get homozygous mutant mice. 
Homozygous mutant offspring were used for clinical chemical analysis compared 
to littermate controls. Homozygous mutant mice of both genders showed 
increased values of urea, potassium, and lipase compared to heterozygous mutant 
and wild-type littermates. In addition, homozygous mutant males showed 
increased levels of AP, and decreased levels of sodium, triglycerides, and 
cholesterol. Homozygous mutant females showed increased cholesterol, and 
decreased total protein levels (Table 4.14).  
 
 
 
 
 
 
 
 
 
   M                    1                  2                   3                  4               M 
460 bp 
353 bp 
 
 
 
107 bp 
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4.2.6 Urine analysis of Pou3f3L423P homozygous mutant mice  
Metabolic cage analysis was performed with homozygous mutant mice compared 
to age-matched heterozygous mutant and wild-type littermate controls. Animals 
were analyzed at the age of 14-15 weeks. Homozygous mutant males showed 
mild polyuria as well as decreased daily uric acid excretion. Homozygous mutant 
females showed decreased uric acid excretion and mild glycosuria. After 24 h 
water deprivation, homozygous mutant mice of both sexes showed increased loss 
of the body weight, and they consumed significantly less food (Table 4.15). 
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4.2.7 Morphological analysis of Pou3f3L423P homozygous mutant mice 
Morphological analysis including body and organ weights was carried out on 
four-month-old homozygous mutant, heterozygous mutant, and wild-type 
littermates with a small group size of n = 3-5. Homozygous mutant animals of 
both sexes showed significantly decreased body and carcass weights as well as a 
decreased nose-to-rump length (Table 4.16). An absolute weight of most organs 
was significantly reduced in homozygous mutants compared to heterozygous 
mutant and wild-type control mice. In comparison to wild-type mice, homozygous 
mutants of both sexes showed decreased relative kidney and liver weights (Table 
4.17, Fig. 4.12). Kidneys from homozygous mutants were, except of the small 
size; light microscopically indistinguishable from those of control littermates (not 
shown). 
 
Fig. 4.12: Representative macroscopic appearance of the kidneys of a four-month-old Pou3f3L423P 
homozygous mutant mouse and a sex-matched wild-type littermate.  
 
 
 
 
 
 
 
 
IV. Results     57 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ta
bl
e 
4.
16
: A
bs
ol
ut
e 
bo
dy
 w
ei
gh
t a
nd
 o
rg
an
 w
ei
gh
ts
 o
f 4
-m
on
th
-o
ld
 m
ic
e 
of
 li
ne
 P
ou
3f
3L
42
3P
  
Fe
m
al
e
t-t
es
t
t-t
es
t
H
om
 (n
 =
 5
)
H
et
 (n
 =
 4
)
W
t (
n 
= 
3)
ho
m
ho
m
he
t
H
om
 (n
 =
 4
)
H
et
 (n
 =
 3
)
W
t (
n 
= 
3)
ho
m
ho
m
he
t
vs
.
vs
.
vs
.
vs
.
vs
.
vs
.
he
t
w
t
w
t
he
t
w
t
w
t
Bo
dy
 w
ei
gh
t (
g)
23
.6
 ±
 2
.0
32
.1
 ±
 4
.1
31
.7
 ±
 1
.4
p<
0.
01
p<
0.
00
1 
  
n.
s.
20
.8
 ±
 1
.6
29
.4
 ±
 0
.6
31
.0
 ±
 5
.7
p<
0.
00
1
p<
0.
05
  
n.
s.
N
os
e-
to
-ru
m
p 
le
ng
th
 (c
m
)
8.
8 
± 
0.
3
9.
8 
± 
0.
3
9.
8 
± 
0.
4
p<
0.
01
p<
0.
01
n.
s.
8.
8 
± 
0.
2
9.
5 
± 
0.
2
9.
9 
± 
0.
3 
p<
0.
01
p<
0.
01
n.
s.
Br
ai
n 
(m
g)
39
5 
± 
12
44
4 
± 
8
46
5 
± 
8
p<
0.
00
1 
  
p<
0.
00
1 
  
n.
s.
40
0 
± 
26
45
6 
± 
10
47
3 
± 
3
p<
0.
01
p<
0.
01
n.
s.
Li
ve
r (
g)
1.
1 
± 
0.
1
1.
5 
± 
0.
2
1.
5 
± 
0.
1
p<
0.
01
p<
0.
00
1 
  
n.
s.
0.
9 
± 
0.
1
1.
3 
± 
0.
1
1.
5 
± 
0.
3
p<
0.
00
1
p<
0.
00
1
n.
s.
K
id
ne
y 
(m
g)
35
3 
± 
40
55
8 
± 
10
4
53
1 
± 
45
p<
0.
01
p<
0.
01
n.
s.
20
2 
± 
28
33
3 
± 
6
34
0 
± 
51
p<
0.
00
1
p<
0.
01
n.
s.
Lu
ng
 (m
g)
14
2 
± 
8
18
3 
± 
22
18
2 
± 
7
p<
0.
01
p<
0.
00
1 
  
n.
s.
14
8 
± 
15
18
0 
± 
8
18
8 
± 
29
p<
0.
05
  
p<
0.
05
  
n.
s.
H
ea
rt 
(m
g)
10
8 
± 
12
13
1 
± 
13
13
5 
± 
16
p<
0.
05
  
p<
0.
05
  
n.
s.
84
 ±
 8
12
0 
± 
11
11
9 
± 
22
p<
0.
01
p<
0.
05
  
n.
s.
Te
sti
s (
m
g)
13
0 
± 
15
15
2 
± 
24
16
7 
± 
18
n.
s.
p<
0.
05
  
n.
s.
U
te
ru
s (
m
g)
84
 ±
 1
8
10
1 
± 
34
11
2 
± 
27
n.
s.
n.
s.
n.
s.
U
rin
ar
y 
bl
ad
de
r (
m
g)
27
 ±
 4
.5
26
 ±
 5
.5
23
 ±
 2
.0
n.
s.
n.
s.
n.
s.
21
 ±
 3
.8
23
 ±
 5
.0
22
 ±
 1
.0
n.
s.
n.
s.
n.
s.
Sp
le
en
 (m
g)
76
 ±
 1
3
85
 ±
 1
0
81
 ±
 3
.0
n.
s.
n.
s.
n.
s.
87
 ±
 5
11
5 
± 
16
11
7 
± 
27
p<
0.
05
  
n.
s.
n.
s.
Ca
rc
as
s (
g)
17
.7
 ±
 1
.3
24
.0
 ±
 3
.4
23
.8
 ±
 1
.5
p<
0.
01
p<
0.
00
1 
  
n.
s.
15
.4
 ±
 1
.5
21
.9
 ±
 1
.1
22
.5
 ±
 4
.6
p<
0.
01
p<
0.
05
  
n.
s.
D
at
a p
re
se
nt
s m
ea
n 
± 
SD
. S
D
: s
ta
nd
ar
d 
de
vi
at
io
n.
 S
tu
de
nt
's 
t-t
es
t, 
p<
0.
05
, p
<0
.0
1,
 an
d 
p<
0.
00
1.
n:
 an
im
al
s a
na
ly
ze
d;
 h
om
: h
om
oz
yg
ou
s m
ut
an
t; 
he
t: 
he
te
ro
zy
go
us
 m
ut
an
t; 
w
t: 
w
ild
-ty
pe
. n
.s:
 n
on
-si
gn
ifi
ca
nt
.  
   
   
   
   
   
   
   
   
   
M
al
e
IV. Results     58 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ta
bl
e 
4.
17
: R
el
at
iv
e 
or
ga
n 
w
ei
gh
ts
 o
f 4
-m
on
th
-o
ld
 m
ic
e 
of
 li
ne
 P
ou
3f
3L
42
3P
  
Ma
le
Fem
ale
t-te
st
t-te
st
Ho
m (
n =
 5)
He
t (n
 = 
4)
Wt
 (n
 = 
3)
hom
hom
het
Ho
m (
n =
 4)
He
t (n
 = 
3)
Wt
 (n
 = 
3)
hom
hom
het
vs.
vs.
vs.
vs.
vs.
vs.
het
wt
wt
het
wt
wt
Bra
in (
mg
)
1.7
 ± 0
.2
1.4
 ± 0
.2
1.5
 ± 0
.1
p<
0.0
5  
n.s
.
n.s
.
1.9
 ± 0
.1
1.6
 ± 0
.0
1.6
 ± 0
.3
p<
0.0
01
n.s
.
n.s
.
Liv
er (
g)
4.3
 ± 0
.2
4.7
 ± 0
.3
4.8
 ± 0
.1
n.s
.
p<
0.0
1
n.s
.
4.2
 ± 0
.1
4.5
 ± 0
.7
4.7
 ± 0
.1
n.s
.
p<
0.0
5  
n.s
.
Kid
ney
 (m
g)
1.5
 ± 0
.2
1.7
 ± 0
.1
1.7
 ± 0
.1
p<
0.0
5  
p<
0.0
5  
n.s
.
1.0
 ± 0
.1
1.1
 ± 0
.0
1.1
 ± 0
.1
p<
0.0
5  
p<
0.0
5  
n.s
.
Lu
ng 
(m
g)
0.6
 ± 0
.04
0.6
 ± 0
.02
0.6
 ± 0
.01
n.s
.
n.s
.
n.s
.
0.7
 ± 0
.05
0.6
 ± 0
.03
0.6
 ± 0
.03
p<
0.0
5  
p<
0.0
5  
n.s
.
He
art 
(m
g)
0.5
 ± 0
.02
0.4
 ± 0
.02
0.4
 ± 0
.05
p<
0.0
5  
n.s
.
n.s
.
0.4
 ± 0
.02
0.4
 ± 0
.05
0.4
 ± 0
.04
n.s
.
n.s
.
n.s
.
Uri
nar
y b
lad
der
 (m
g)
0.1
1 ±
 0.0
1
0.0
8 ±
 0.0
1
0.0
7 ±
 0.0
1
p<
0.0
1
 p<
0.0
1
n.s
.
0.1
0 ±
 0.0
1
0.0
8 ±
 0.0
2
0.0
7 ±
 0.0
1
n.s
.
p<
0.0
5  
n.s
.
Da
ta p
res
ent
s m
ean
 ± S
D. 
SD
: st
and
ard
 de
via
tion
. St
ude
nt's
 t-t
est
, p<
0.0
5; p
<0
.01
; p<
0.0
01.
Ho
m: 
hom
ozy
gou
s m
uta
nt; 
het
: he
tero
zyg
ous
 mu
tan
t; w
t: w
ild-
typ
e. n
.s: 
non
-sig
nif
ica
nt; 
n: a
nim
als
 an
aly
zed
.
IV. Results     59 
4.3 Line HST015 
4.3.1 Linkage analysis of the causative mutation 
Phenotypically heterozygous mutant mice on the C3H genetic background 
showed a significantly reduced breeding capacity. However, by mating 
phenotypically heterozygous mutant mice with albino BALB/c mice, we were 
able to get G1 hybrid mice. G1 offspring were screened for increased plasma urea 
levels (>70 mg/dl for males and >65 mg/dl for females as cut-off values) at the 
age of 12 and 15 weeks. Phenotypically mutant G1 animals were mated with 
BALB/c mice to produce G2 offspring. Only about 25% G2 animals showed 
increased plasma urea levels and this was not consistent in the second 
measurement, however they showed decreased body weight and/or aggressive 
and/or hyperactive behaviour. Phenotypically mutant G2 backcross mice were 
further mated with BALB/c mice to get G3 offspring. Some phenotypically 
mutant G2 mice were failed to produce offspring and we also observed that more 
pigmented G3 mice showed increased plasma urea levels as compared to albino 
G3 mice (Table 4.18). In addition, 58 G2 mice were also analyzed for coat color 
and mutant phenotype defined as increased plasma urea levels. Out of 58 G2 
mice, 15 pigmented mice were phenotypically mutant and 10 pigmented mice 
were wild-type (χ2 value = 4.0), whereas 9 albino mice were phenotypically 
mutant and 24 albino mice were wild-type (χ2 value = 21.1). Thus, it was assumed 
that it might be a linkage between coat color and mutant phenotype. BALB/c mice 
show an albino coat color due to the recessive mutation Tyrc/c on chromosome 7 
(94.5 Mb). 
To verify the linkage, we re-analyzed data from the ENU-induced mutant line 
HST001 with increased plasma urea levels as primary phenotype and the 
causative dominant mutation UmodC93F on chromosome 7 (126.6 Mb) as the 
linkage analysis was also carried out with G2 backcross mice produced with the 
BALB/c inbred strain (Prückl 2011). By analyzing the coat color of G2 backcross 
animals of line HST001, strong linkage between coat color and mutant phenotype 
was observed (Table 4.18).  
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Table 4.18: Phenotypic analysis of coat color and mutant phenotype (increased 
plasma urea levels) in backcross animals of line HST001 and HST015 
 HST001 (G2)  HST015 (G3)  
Coat color Phenotypically 
mutant 
Phenotypically 
wild-type 
χ2 
value 
Phenotypically 
mutant 
Phenotypically 
wild-type 
χ2 
value 
Pigmented 79 (89%) 23 (21%) 30 30 (83%) 6 (11%) 43 
Albino 10 (11%) 86 (79%) 64 6 (17%) 48 (89%) 60 
χ2 value 60 33  43 60  
G2: Backcross animals from the second backcross generation with BALB/c mice; G3: Backcross 
animals from the third backcross generation with BALB/c mice 
4.3.2 Fine mapping of chromosome 7 
Fine mapping was carried out using polymorphic markers of chromosome 7 
(Table 4.19). Twenty four phenotypically mutant G2-G3 backcross animals were 
analyzed. The markers D7Mit276 and D7Mit90 showed the heterozygous 
C3H/BALB/c genotype in all mice examined.  
Table 4.19: Fine mapping analysis of chromosome 7 in line HST015 
Marker Locus (Mb) Heterozygous 
C3H/BALB/c 
BALB/c/BALB/c Total 
D7Mit230 56.7 22  2  24 
D7Mit276 69.4 24  0  24 
D7Mit90 87.5 24  0  24 
D7Mit323 108.0 22  2  24 
D7Mit40 123.9 19  5  24 
D7Mit68 132.4 17  7  24 
 
4.3.3 Candidate gene analysis 
The two candidate genes Tomt and Chd2 were selected for sequence analysis 
(Table 4.20). Genomic DNA and RNA was extracted from two phenotypically 
heterozygous mutant mice (one on the C3H genetic background and one on the 
mixed C3H×BALB/c genetic background) and two phenotypically wild-type mice 
on the C3H genetic background. For Tomt, the exonic regions were sequenced, 
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whereas for Chd2 cDNA transcript sequencing is going on (Fig. 4.13). Sequence 
analysis of Tomt resulted in the identical sequence in phenotypically heterozygous 
mutant mice and wild-type mice. 
Table 4.20: Candidate genes in line HST015 and their published phenotype data 
Gene Position 
(Mb) 
Exons Polypeptide length (aa) Mutant phenotype 
(http://www.informatics.jax.org/ 
Tomt 109.0 4 258 ENU-induced homozygous mutants 
exhibited marked hyperactivity, 
bidirectional circling and head-
tossing. These behaviours were 
suppressed during sleep and 
nursing. Homozygous mutant males 
exhibited increased male to male 
aggression (Du et al. 2008). 
Chd2 80.5 39 1827 Gene trapped homozygous mutant 
mice exhibited early postnatal 
lethality associated with fetal 
growth retardation.  Heterozygous 
mutant mice exhibited postnatal 
lethality and premature death after 
weaning associated with growth 
retardation and multi-organ defects 
(Marfella et al. 2006). 
 
A) 
 
B) 
 
Fig. 4.13: Position and length of PCR products amplified on the candidate genes of line HST015. 
A) Tomt gene and B) Chd2 cDNA. E: exon 
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4.3.4 Clinical chemical analysis of phenotypically heterozygous mutant mice  
After rederivation of line HST015 in the mouse facility of the Moorversuchsgut 
by IVF, phenotypically heterozygous mutant mice showed reduced fertility. To 
avoid physical stress for the animals, only small amounts of blood were taken and 
used in the analysis especially of parameters which are predictive for the kidney 
function. Phenotypically heterozygous mutant mice on the C3H genetic 
background were defined by increased levels of plasma urea in both sexes. Plasma 
levels of total protein and uric acid were significantly decreased in phenotypically 
heterozygous mutant mice as compared to littermate controls. Phenotypically 
heterozygous mutant females showed increased creatinine-J levels (Table 4.21). 
Table 4.21: Plasma data of 12-to14-week-old mice on the C3H genetic 
background of line HST015 
 
4.3.5 Phenotypical analysis of backcross mice 
Mice on the mixed C3H×BALB/c genetic background were phenotypically 
analyzed (58 G2 and 80 G3 mice) for increased plasma urea levels. Using >70 
mg/dl for males and >65 mg/dl for females as cut-off values, the 138 G2-G3 
backcross mice were classified in 60 (43%) heterozygous mutant mice and 78 
(57%) wild-type mice. In addition, we observed growth retarded pups at birth. 
Therefore, we measured the body weight at the age of 3 months in both groups 
classified by the increased plasma urea levels. Phenotypically heterozygous 
mutant mice exhibited growth retardation. We also carried out sections of 
phenotypically heterozygous mutant females and found that some females had 
increased ovaries and uteri (Fig. 4.14). 
 
Male Female
Ph. het (n = 7) Ph. wt (n = 14)    t-test Ph. het (n = 9) Ph. wt (n = 13)    t-test
(het vs. wt) (het vs. wt)
Total protein (g/dl) 5.2 ± 0.2 5.6 ± 0.3 p<0.01 5.3 ± 0.3 5.6 ± 0.3 p<0.05
Creatinine-J (µmol/l) 32 ±  2.1 33 ± 2.2 n.s. 34 ± 2.3 32 ± 1.8 p<0.05
Urea (mg/dl) 89 ± 22 59 ± 6 p<0.001 81 ± 9 48 ± 9 p<0.001
Uric acid (mg/dl) 2.3 ± 1.2 4.9 ± 1.2 p<0.001 1.5 ± 0.6 3.5 ± 1.2 p<0.001
Data represents the means ± SD; SD: standard deviation. Student's t-test, p<0.05, p<0.01, and p<0.001.
n: number of the animals analyzed. ns: non-significant.
Ph. het: phenotypically heterozygous mutant mice; Ph. wt: phenotypically wild-type mice.
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Fig. 4.14: Analysis of G2-G3 backcross mice of line HST015 on the mixed C3H×BALB/c genetic 
background. a) Classification into phenotypically heterozygous mutants and wild-type mice 
according to their plasma urea levels. b) One of the one-day-old pups is showing growth 
retardation. c) Body weight of three-month-old female mice which were classified into 
phenotypically heterozygous mutants and wild-type mice according to the plasma urea levels (see 
a). d) Ovaries from a phenotypically heterozygous mutant female (arrow). Data represents the 
mean ± SD. Student’s, t-test p<0.05a, p<0.001c. Ph wt: phenotypically wild-type; Ph het: 
phenotypically heterozygous mutant; n: number of animals analyzed. 
4.4 Line CLP001 
4.4.1 Sequence analysis of the gene Gsdma3  
Linkage analysis and fine mapping was already carried out independent of this 
study, and the causative mutation was mapped to a defined region around 100 Mb 
on chromosome 11. Gsdma3 was chosen for the sequence analysis (Fig. 4.15; 
http://www.informatics.jax.org/).  
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Fig. 4.15: Position and length of PCR products amplified on the gene Gsdma3. E: exon 
Sequence analysis revealed a T→A transversion at nt 1158 
(ENSMUST00000073295), which leads to the amino acid exchange from 
isoleucine to asparagine at aa position 359 (Fig. 4.16). The name of line CLP001 
was designated as Gsdma3I359N. 
 
Fig. 4.16: Electropherogram of the sequence of Gsdma3. Sequence from A) a wild-type mouse, B) 
a phenotypically heterozygous mutant mouse, and C) a phenotypically homozygous mutant 
mouse. The arrow shows the position of the T to A transversion which leads to the amino acid 
exchange from isoleucine to asparagine at aa position 359. 
4.4.2 Allelic differentiation of the Gsdma3I359N mutant mice by ARMS-PCR 
Allelic differentiation was carried out by the amplification refractory mutation 
system PCR (ARMS-PCR; see 3.3.4.2). The allele-specific reverse primer INT1 
(5’ tttctccaaggattttactaaaa 3’) and the forward primer EXT1 (5’ 
caaatgagcatatgaatgaatag 3’) were used for amplifying the wild-type allele (230 
bp). For the amplification of the mutant allele (144 bp), the allele-specific forward 
primer INT2 (5’ ctaactgaagaacaactgaataa 3’) and the reverse primer EXT2 (5’ 
atgttcccacaagttctagcg 3’) were used. A 374 bp long fragment was amplified from 
both external primers (Fig. 4.17a and b). 
  E1              E2                E3             E4                E5      E6             E7                    E8     E9                          E10  E11 
11.73 kb 
278 bp 
368 bp 
477  bp 226  bp 735  bp  178  bp 848  bp 725  bp 
                    A                                                             B                                                                  C 
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Fig. 4.17a: Scheme of the ARMS-PCR. The mutant allele-specific primer INT2 amplifies the 144 
bp PCR product with primer EXT2. Primer INT1 (wild-type allele-specific) amplifies the 230 bp 
wild-type PCR product. In addition, a 374 bp long PCR product is derived from primers EXT1 and 
EXT2. 
 
Fig. 4.17b: Electrophoretic pattern of the allele-specific PCR in line Gsdma3I359N. Lanes 1, 2, 3: 
homozygous mutant mice; lanes 4, 5, 6: heterozygous mutant mice; lanes 7, 8: wild-type mice. 
Lane M is the pUC 8 marker. 
4.4.3 Analysis of alopecia in Gsdma3I359N mutant mice 
Gsdma3I359N heterozygous mutant mice exhibited alopecia. Therefore, the onset 
and the course of hair loss were studied in homozygous mutants and heterozygous 
mutants compared with wild-type littermates. In heterozygous mutant mice, hair 
loss started from 3 weeks of age from the neck and complete hair loss appeared at 
6 weeks of age. Following this, regeneration of hair growth started resulting in a 
complete loose and spare hair coat at 8 weeks of age. Hair loss again started from 
9 weeks of age resulting in complete baldness at 14 weeks of age. Homozygous 
mutant mice showed a pattern of hair loss which is similar to the heterozygous 
mutants. However, after regeneration of the spare and loose hair coat, the second 
5‘ 
5‘3‘ 
3‘
Point mutation 
EXT1 
 374 bp
144 bp
230 bp
INT 2
EXT 2 
INT 1
M           1        2            3        4         5          6         7         8          M 
374 bp 
230 bp 
144 bp 
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cycle of hair loss was more pronounced resulting in complete baldness at 10-11 
weeks of age (Fig 4.18).  
 
Fig. 4.18: Course of the hair loss in line Gsdma3I359N. Hair loss starts from the neck at 3 weeks of 
age. At 8 weeks of age, loose and spare hair is visible after the regeneration in homozygous mutant 
and heterozygous mutant animals. Complete baldness appears again in homozygous mutant 
animals at 10-11 weeks of age and in heterozygous mutants at 14 weeks of age. Hom: homozygous 
mutant mice; het: heterozygous mutant mice; wt: wild-type mice. 
4.4.4 Clinical chemical analysis of Gsdma3I359N mutant mice 
Clinical chemical blood analysis was carried out using homozygous mutant, 
heterozygous mutant and wild-type mice on the C3H genetic background. 
Compared to wild-type controls, homozygous mutant mice of both sexes showed 
a decreased activity of alkaline phosphatase (Table 4.22). 
4.4.5 Morphological analysis of Gsdma3I359N mutant mice 
Morphological analysis of body and organ weights was also carried out. 
Homozygous mutant and heterozygous mutant animals were viable and fertile. 
Homozygous mutant males exhibited a decreased absolute and relative weight of 
the testis as well as an increased absolute and relative weight of the spleen 
compared to wild-type littermates. Homozygous mutant and heterozygous mutant 
females showed an increased absolute and relative weight of the heart compared 
to wild-type littermates (Table 4.23). 
 
 
 
 
   3 weeks (Het)       8 weeks (Het)           12 weeks (Het)     12 weeks (Hom)        12 weeks (Wt)      
IV. Results     67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ta
bl
e 
4.
22
: P
la
sm
a 
da
ta
 o
f 1
2-
to
 1
4-
w
ee
k-
ol
d 
m
ic
e 
of
 li
ne
 G
sd
m
a3
I3
59
N
  
M
al
e
Fe
m
al
e
H
om
 (n
 =
 6
)
H
et
 (n
 =
 8
)
W
t (
n 
= 
8)
t-t
es
t
H
om
 (n
 =
 8
)
H
et
 (n
 =
 1
1)
W
t (
n 
= 
9)
t-t
es
t
ho
m
ho
m
he
t
ho
m
ho
m
he
t
vs
.
vs
.
vs
.
vs
.
vs
.
vs
.
he
t
w
t
w
t
he
t
w
t
w
t
N
a 
(m
m
ol
/l)
14
6 
± 
3
14
6 
± 
5
14
8 
± 
4
n.
s.
n.
s.
n.
s.
14
6 
± 
5
14
7 
± 
9
14
7 
± 
11
n.
s.
n.
s.
n.
s.
K
 (m
m
ol
/l)
4.
5 
± 
0.
5
4.
4 
± 
0.
4
4.
5 
± 
0.
4
n.
s.
n.
s.
n.
s.
4.
3 
± 
0.
4
4.
3 
± 
0.
5
4.
2 
± 
0.
7
n.
s.
n.
s.
n.
s.
C
a 
(m
m
ol
/l)
2.
3 
± 
0.
1
2.
3 
± 
0.
1
2.
2 
± 
0.
1
n.
s.
n.
s.
n.
s.
2.
3 
± 
0.
1
2.
3 
± 
0.
1
2.
3 
± 
0.
2
n.
s.
n.
s.
n.
s.
C
l (
m
m
ol
/l)
10
8 
± 
5
10
8 
± 
7
11
0 
± 
6
n.
s.
n.
s.
n.
s.
11
0 
± 
7
11
4 
± 
8
11
6 
± 
8
n.
s.
n.
s.
n.
s.
Pi
 (m
m
ol
/l)
1.
8 
± 
0.
1
2.
0 
± 
0.
5
1.
7 
± 
0.
4
n.
s.
n.
s.
n.
s.
2.
0 
± 
0.
3
2.
1 
± 
0.
4
2.
3 
± 
0.
4
n.
s.
n.
s.
n.
s.
To
ta
l p
ro
te
in
 (g
/l)
49
 ±
 2
49
 ±
 2
51
 ±
 2
n.
s.
n.
s.
n.
s.
50
 ±
 2
53
 ±
 5
53
 ±
 4
n.
s.
n.
s.
n.
s.
C
re
at
in
in
e-
J 
(µ
m
ol
/l)
26
 ±
 2
25
 ±
 1
27
 ±
 4
n.
s.
n.
s.
n.
s.
26
 ±
 3
28
 ±
 2
27
 ±
 3
n.
s.
n.
s.
n.
s.
C
re
at
in
in
e-
E 
(µ
m
ol
/l)
8.
7 
± 
1.
9
9.
4 
± 
1.
5
12
.1
 ±
 8
.7
n.
s.
n.
s.
n.
s.
9.
3 
± 
1.
8
8.
7 
± 
1.
6
9.
6 
± 
2.
5
n.
s.
n.
s.
n.
s.
U
re
a 
(m
g/
dl
)
45
 ±
 5
50
 ±
 5
53
 ±
 5
n.
s.
p<
0.
05
n.
s.
43
 ±
 6
49
 ±
 8
46
 ±
 7
n.
s.
n.
s.
n.
s.
U
ric
 a
ci
d 
(m
g/
dl
)
4.
0 
± 
1.
7
4.
9 
± 
2.
6
4.
9 
± 
1.
5
n.
s.
n.
s.
n.
s.
2.
5 
± 
2.
0
3.
4 
± 
2.
4
2.
9 
± 
1.
7
n.
s.
n.
s.
n.
s.
C
ho
le
st
er
ol
 (m
m
ol
/l)
3.
6 
± 
0.
1
3.
3 
± 
0.
3
3.
5 
± 
0.
2
p<
0.
05
n.
s.
n.
s.
2.
9 
± 
0.
2
2.
8 
± 
0.
2
3.
0 
± 
0.
3
n.
s.
n.
s.
n.
s.
Tr
ig
ly
ce
rid
es
 (m
m
ol
/l)
2.
1 
± 
0.
6
1.
9 
± 
0.
7
2.
1 
± 
0.
6
n.
s.
n.
s.
n.
s.
1.
1 
± 
0.
3
1.
8 
± 
0.
7
1.
8 
± 
0.
8
p<
0.
05
p<
0.
05
n.
s.
C
K
 (U
/l)
91
 ±
 4
7
23
1 
± 
26
9
33
0 
± 
42
5
n.
s.
n.
s.
n.
s.
33
3 
± 
42
7
23
0 
± 
24
4
21
5 
± 
13
6
n.
s.
n.
s.
n.
s.
A
LT
 (U
/l)
29
 ±
 1
0
43
 ±
 2
4
39
 ±
 1
7
n.
s.
n.
s.
n.
s.
46
 ±
 2
3
52
 ±
 2
4
54
 ±
 3
4
n.
s.
n.
s.
n.
s.
A
ST
 (U
/l)
55
 ±
 1
5
62
 ±
 2
7
55
 ±
 1
8
n.
s.
n.
s.
n.
s.
80
 ±
 3
5
66
 ±
 2
2
56
 ±
 1
4
n.
s.
n.
s.
n.
s.
A
P 
(U
/l)
91
 ±
 6
98
 ±
 1
8
12
9 
± 
24
n.
s.
p<
0.
01
p<
0.
05
12
4 
± 
6
12
6 
± 
20
15
2 
± 
28
n.
s.
p<
0.
05
n.
s.
A
m
yl
as
e 
(U
/l)
N
D
18
85
 ±
 1
66
20
46
 ±
 1
39
N
D
N
D
n.
s.
17
65
 ±
 3
5
18
32
 ±
 1
09
18
42
 ±
 1
99
n.
s.
n.
s.
n.
s.
G
lu
co
se
 (m
g/
dl
)
13
5 
± 
25
12
7 
± 
28
11
9 
± 
19
n.
s.
n.
s.
n.
s.
12
5 
± 
15
13
1 
± 
25
13
7 
± 
27
n.
s.
n.
s.
n.
s.
A
lb
um
in
 (g
/d
l)
2.
5 
± 
0.
2
2.
4 
± 
0.
2
2.
3 
± 
0.
1
n.
s.
p<
0.
05
n.
s.
2.
6 
± 
0.
1
2.
6 
± 
0.
2
2.
5 
± 
0.
4
n.
s.
n.
s.
n.
s.
Fe
rr
iti
n 
(µ
g/
l)
77
 ±
 1
0
68
 ±
 3
3
57
 ±
 4
3
n.
s.
n.
s.
n.
s.
89
 ±
 3
9
44
 ±
 3
4
44
 ±
 4
1
p<
0.
05
p<
0.
05
n.
s.
Tr
an
sf
er
rin
 (m
g/
dl
)
15
6 
± 
2.
2
15
0 
± 
4.
5
15
3 
± 
6.
5
p<
0.
01
n.
s.
n.
s.
16
0 
± 
1.
7
15
5 
± 
4.
4
15
9 
± 
4.
4
p<
0.
01
n.
s.
n.
s.
Li
pa
se
 (U
/l)
43
 ±
 5
49
 ±
 1
3
53
 ±
 1
2
n.
s.
n.
s.
n.
s.
52
 ±
 4
52
 ±
 8
57
 ±
 1
0
n.
s.
n.
s.
n.
s.
C
-r
ea
ct
iv
e 
pr
ot
ei
n 
(m
g/
l)
1.
4 
± 
0.
7
2.
0 
± 
2.
2
0.
6 
± 
0.
6
n.
s.
n.
s.
n.
s.
1.
6 
± 
0.
7
1.
4 
± 
1.
0
1.
4 
± 
1.
2
n.
s.
n.
s.
n.
s.
La
ct
at
e 
(m
m
ol
/l)
10
 ±
 1
.8
11
 ±
 1
.5
11
 ±
 1
.3
n.
s.
n.
s.
n.
s.
10
 ±
 2
.0
10
 ±
 1
.1
10
 ±
 1
.4
n.
s.
n.
s.
n.
s.
D
at
a 
re
pr
es
en
ts
 th
e 
m
ea
ns
 ±
 S
D
; S
D
: s
ta
nd
ar
d 
de
vi
at
io
n.
 S
tu
de
nt
's 
t-t
es
t, 
p<
0.
05
, p
<0
.0
1,
 a
nd
 p
<0
.0
01
.
n:
 n
um
be
r o
f t
he
 a
ni
m
al
s 
an
al
yz
ed
. n
s:
 n
on
-s
ig
ni
fic
an
t; 
N
D
: n
ot
 d
on
e
H
om
: h
om
oz
yg
ou
s 
m
ut
an
t m
ic
e;
 H
et
: h
et
er
oz
yg
ou
s 
m
ut
an
t m
ic
e;
 W
t: 
w
ild
-ty
pe
 m
ic
e.
C
K
: c
re
at
in
e 
ki
na
se
; A
LT
: a
la
ni
ne
 a
m
in
ot
ra
ns
fe
ra
se
; A
ST
: a
sp
ar
ta
te
 a
m
in
ot
ra
ns
fe
ra
se
; A
P:
 a
lk
al
in
e 
ph
os
ph
at
as
e.
IV. Results     68 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ta
bl
e 
4.
23
: A
bs
ol
ut
e 
bo
dy
 w
ei
gh
t a
nd
 o
rg
an
 w
ei
gh
ts
 o
f 4
-m
on
th
-o
ld
 m
ic
e 
of
 li
ne
 G
sd
m
a3
I3
59
N
  
M
ale
Fe
ma
le
t-t
est
t-t
est
ho
m
ho
m
he
t
ho
m
ho
m
he
t
Ho
m 
(n 
= 4
)
He
t (
n =
 6)
W
t (
n =
 4)
vs
.
vs
.
vs
.
Ho
m 
(n 
= 5
)
He
t (
n =
 8)
W
t (
n =
 6)
vs
.
vs
.
vs
.
he
t
wt
wt
he
t
wt
wt
Bo
dy
 w
eig
ht 
(g)
28
.4 
± 1
.0
27
.8 
± 3
.0
26
.1 
± 2
.0
n.s
.
n.s
.
n.s
.
23
.3 
± 1
.2
24
.6 
± 2
.4
23
.8 
± 2
.1
n.s
.
n.s
.
n.s
.
No
se-
to-
rum
p l
en
gth
 (c
m)
9.1
 ± 
0.1
9.0
 ± 
0.5
9.2
 ± 
0.0
n.s
.
n.s
.
n.s
.
9.1
 ± 
0.1
8.9
 ± 
0.4
8.9
 ± 
0.3
n.s
.
n.s
.
n.s
.
Br
ain
 (m
g)
43
1 ±
 14
43
9 ±
 17
44
8 ±
 21
n.s
.
n.s
.
n.s
.
44
9 ±
 7
44
8 ±
 14
46
0 ±
 10
n.s
.
n.s
.
n.s
.
Li
ve
r (
g)
1.6
 ± 
0.3
1.7
 ± 
0.2
1.4
 ± 
0.1
n.s
.
n.s
.
n.s
.
1.3
 ± 
0.1
1.4
 ± 
0.2
1.3
 ± 
0.1
n.s
.
n.s
.
n.s
.
Ki
dn
ey
 (m
g)
57
1 ±
 60
54
6 ±
 76
50
6 ±
 55
n.s
.
n.s
.
n.s
.
35
0 ±
 20
35
1 ±
 29
32
7 ±
 16
n.s
.
n.s
.
n.s
.
Lu
ng
 (m
g)
17
9 ±
 16
17
8 ±
 27
16
7 ±
 18
n.s
.
n.s
.
n.s
.
17
6 ±
 16
17
2 ±
 11
17
0 ±
 19
n.s
.
n.s
.
n.s
.
He
art
 (m
g)
12
8 ±
 14
13
1 ±
 15
12
3 ±
 16
n.s
.
n.s
.
n.s
.
11
5 ±
 13
12
0 ±
 6
10
2 ±
 5
n.s
.
p<
0.0
5c 
p<
0.0
01
c 
Te
sti
s (
mg
)
16
4 ±
 7
16
7 ±
 18
18
0 ±
 8
n.s
.
p<
0.0
5a 
 
n.s
.
Ut
eru
s (
mg
)
12
9 ±
 28
12
3 ±
 22
13
1 ±
 43
n.s
.
n.s
.
n.s
.
Ur
ina
ry 
bla
dd
er 
(m
g)
25
 ± 
4.2
23
 ± 
3.7
27
 ± 
4.9
n.s
.
n.s
.
n.s
.
21
 ± 
2.4
20
 ± 
2.5
20
 ± 
4.3
n.s
.
n.s
.
n.s
.
Sp
lee
n (
mg
)
10
3 ±
 16
95
 ± 
20
77
 ± 
11
n.s
.
p<
0.0
5b 
 
n.s
.
13
8 ±
 53
13
1 ±
 32
11
8 ±
 19
n.s
.
n.s
.
n.s
.
Ca
rca
ss 
(g)
20
.7 
± 1
.4
20
.9 
± 1
.5
18
.4 
± 1
.8
n.s
.
n.s
.
n.s
.
17
.1 
± 1
.5
18
.0 
± 1
.8
17
.6 
± 1
.1
n.s
.
n.s
.
n.s
.
Da
ta 
rep
res
en
t m
ea
ns
 ± 
SD
. S
D:
 st
an
da
rd 
de
via
tio
n. 
Stu
de
nt'
s t
-te
st,
 p<
0.0
5, 
p<
0.0
1, 
an
d p
<0
.00
1.
n: 
an
im
als
 an
aly
ze
d; 
ho
m:
 ho
mo
zy
go
us
 m
uta
nt;
 he
t: h
ete
roz
yg
ou
s m
uta
nt;
 w
t: w
ild
-ty
pe
; n
.s:
 no
n-s
ign
ifi
ca
nt.
 
a: 
the
 re
lat
ive
 te
sti
s w
eig
ht 
of 
the
 ho
mo
zy
go
us
 m
uta
nt 
ma
les
 is
 si
gn
ifc
an
tly
 de
cre
ase
d (
p<
0.0
5).
b: 
the
 re
lat
ive
 sp
lee
n w
eig
ht 
is 
sig
nif
ica
ntl
y i
nc
rea
sed
 in
 ho
mo
zy
go
us
 m
uta
nt 
ma
les
 (p
<0
.05
). 
c: 
the
 re
lat
ive
 he
art
 w
eig
ht 
is 
sig
nif
ica
ntl
y i
nc
rea
sed
 in
 ho
mo
zy
go
us
 m
uta
nt 
an
d h
ete
roz
yg
ou
s m
uta
nt 
fem
ale
s (
p<
0.0
5).
 
IV. Results     69 
4.5 Generation of congenic lines 
Congenic lines are going to be established using C57BL/6 and BALB/c mice as 
recipient genetic background for the lines HST014, HST011, and HST015 (Table 
4.24). The production of the congenic lines is continuing. In the lines HST014 and 
HST011, the causative mutation is used to select the mice for the breeding of the 
next backcross generation. In line HST015, mice showing increased plasma urea 
levels are used for the breeding of the next backcross generation. 
Table 4.24: Backcross generations produced for the lines HST014, HST011 and 
HST015 
Line Generation 
 C57BL/6 BALB/c 
HST014 3 6 
HST011 3 2 
HST015 0 5 
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V. DISCUSSION 
The goal of the present study was to examine four ENU-induced mutant mouse 
lines for the causative mutation and the basal clinical chemical and morphological 
phenotypes. Three lines harbour a dominant mutation (HST014, HST015, and 
CLP001) and a fourth line harbours a recessive mutation (HST011 = UREHR2). 
The mutant lines were maintained on the C3H genetic background. Breeding data 
revealed that the aberrant phenotype of each line is caused by a mutation of a 
single genomic locus. 
ENU is a potent mutagen and induces primarily point mutations in the 
spermatogonial stem cells (Russell et al. 1979). Search for published ENU-
induced mutants (as of 31.03.2011) in the “phenotypes and alleles” section of the 
MGI database (http://www.informatics.jax.org/searches/allele_form.shtml) 
revealed 2,282 alleles and 1,823 genes/markers. Among them, 73 alleles and 61 
genes/markers are described for influencing the renal or urinary system as primary 
or secondary phenotype. In the phenotype-driven Munich ENU mouse 
mutagenesis project, the generation of several mutant lines using increased plasma 
urea levels as primary phenotype with dominant or recessive mutation has been 
described on the C3H inbred genetic background (Aigner et al. 2007). The lines 
described includes line HST011 (= UREHR2). 
5.1 Line HST014 exhibiting the mutation Kctd1I27N 
Line HST014 was established in the screen for dominant mutations showing 
increased plasma urea levels. Linkage analysis revealed the causative mutation on 
the proximal region of chromosome 18. Sequence analysis of the candidate gene 
Kctd1 (15.1 Mb) revealed a T to A transversion which leads to the amino acid 
exchange from isoleucine to asparagine at position 27. The probability of the 
existence of confounding nonsegregating mutations in the chromosomal region of 
1 bp to 20 Mb of chromosome 18 is significantly low (p<0.01) 
((http://zeon.well.ox.ac.uk/git-bin/enuMutRat; Keays et al. 2007). We calculated 
the mutation rate in this region because the highest linkage was found at 21.5 Mb 
(D18Mit68) and data showed that the candidate region is clearly proximal to 21.5 
Mb. 
Kctd1 is a member of the potassium channel tetramerization domain containing 
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(Kctd) gene family. The name is based on the fact that the N-termini of KCTD 
proteins and some voltage-gated K + (Kv) channels are homologous (Lee et al. 
1994, Shen et al. 1993). The KCTD1 protein contains a N-terminal BTB (broad-
complex, tramtrack, and bric-a-brac) domain. The zinc finger proteins BTB are 
protein–protein interaction modules that mediate both self-association and 
interaction with non-BTB partners. BTB domain containing proteins show 
significant conservation of the core fold. The domain mediates the homodimeric 
and homotetrameric assembly of transcription factors and Kv channels, 
respectively (Stogios et al. 2005). KCTD proteins have been anticipated to bind to 
and regulate Kv channels (Abbott and Goldstein 1998). However, the biological 
function of KCTD proteins remains unclear. Expression studies revealed high 
levels in fetal tissues and low levels in adults which may implicate their role 
during development (Gamse et al. 2005). The KCTD proteins have been 
demonstrated to participate in a wide variety of cellular functions including 
transcription regulation, cellular proliferation, apoptosis, cell morphology, ion 
channel assembly, and protein degradation through ubiquitination. The KCTD1 
protein is expressed in the mammary gland, kidney, brain, and ovary (Ding et al. 
2008). We also found mRNA expression in the kidney. It has been suggested that 
KCTD1 is a nuclear protein and functions as a transcriptional repressor by 
mediating protein-protein interactions through a BTB domain for the AP-2 family 
by inhibiting its transactivation (Ding et al. 2009).  
The well curated MGI database (http://www.informatics.jax.org) harbouring 
knockout as well as mutant mouse alleles includes no information about published 
Kctd1 mouse mutants. Thus, this is the first report about a Kctd1 mutant allele in 
mice. Kctd1I27N heterozygous mutant mice were mated to produce homozygous 
mutant mice. At 3 month of age, we could not detect homozygous mutant 
offspring. The analysis of fetuses at the stage E17.5 showed the expected number 
of homozygous mutant animals. Thus, homozygous mutant animals showed early 
postnatal mortality. Further experiments have to be carried out to assess the time 
point and the cause of the early postnatal mortality in homozygous mutant mice. 
These data supports the role of KCTD1 in mammalian development. The clinical 
chemical blood analysis as well as metabolic cage analysis of three-month-old 
heterozygous mutant mice revealed signs of impaired kidney functions like 
increased urea, creatinine, and potassium levels as well as increase in water 
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intake, mild polyuria, and distinct hypercalciuria.  
However, there is no report available about the renal function of KCTD1. One of 
the regimes of the reabsorption of the glomerular filtrate is located in the TALH 
cells where up to 20% of the glomerular filtrate is reabsorbed. Numerous ion 
transporters, such as NKCC2, ROMK, Na+/H+ exchanger (NHE3), KCC4, and 
ClC-Kb are expressed in TALH (Gamba 2005). TALH dysfunction leads to the 
impairment of urine concentration ability and reabsorption of ions as it has been 
observed in another ENU-induced mutant line showing nephropathy (Kemter et 
al. 2010) or with impaired androgen hormones (Hsu et al. 2010). These data 
suggest the role of KCTD1 protein in renal physiology. However, the cell-specific 
expression of KCTD1 in the kidney has yet to be analyzed.  
Kctd1 inhibits the transactivation of the AP-2 family (Ding et al. 2009). 
Transcription factor AP-2 beta (a member of the AP-2 family) homozygous 
knockout mice have been described showing neonatal or postnatal lethality with 
renal kidney cysts, depending on the strain background. Homozygous knockout 
mice on the congenic 129P2 genetic background had tremors, polydactyly, 
defective tubular secretory function and ion homeostasis, hypocalcemia, 
phosphatemia, hyperuremia, and terminal renal failure (Moser et al. 1997, 2003). 
Using the Kctd1 mutation on the C3H genetic background, the generation of 
congenic lines on the BALB/c and C57BL/6 genetic background is underway, to 
analyze the mutant phenotype on different genetic backgrounds. Kctd1 mutations 
in humans are also not reported so far (http://www.ncbi.nlm.nih.gov/omim). 
5.2 Line HST011 exhibiting the mutation Pou3f3L423P 
Phenotypically mutant mice of line HST011 (= UREHR2) showed the recessive 
inheritance of increased plasma urea values. Re-analysis of the linkage data 
detected the causative mutation on chromosome 1. Sequence analysis of the gene 
Pou3f3 (42.7 Mb) revealed a T→C missense mutation which leads to the amino 
acid exchange from leucine to proline at position 423, hence the name of line 
HST011 was designated as Pou3f3L423P. The probability of the existence of 
confounding nonsegregating mutations in the determined chromosomal region of 
33.2-65.8 Mb of chromosome 1 is low (p<0.05) ((http://zeon.well.ox.ac.uk/git-
bin/enuMutRat; Keays et al. 2007). 
Pou3f3 (Brn1, brain-1) is a member of the class III POU domain transcription 
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factors. POU transcription factors carry a common DNA binding motif called 
POU domain and regulate a variety of developmental processes (Finney et al. 
1988, Herr et al. 1988). The POU domain contains the well-characterized DNA-
binding motif called as homeodomain. The homeodomains are involved in the 
transcriptional regulation of developmental processes (Phillips and Luisi 2000). 
Pou3f3 is an intronless gene and is GC rich (74%) throughout the coding region 
(Sumiyama et al. 1996). Pou3f3 is expressed in the central nervous system (He et 
al. 1989, McEvilly et al. 2002) and the kidney (Nakai et al. 2003) during 
embryonic development.  
Upon searching the MGI database (http://www.informatics.jax.org) for Pou3f3 
mutant phenotypes, two Pou3f3 knockout mutant mouse lines are found. The first 
knockout mouse line was established by replacing the gene sequences which 
encode the first 476 amino acids with a PGK-neo cassette via homologous 
recombination on an unspecified genetic background (McEvilly et al. 2002). The 
second knockout line was also established by using a PGK-neo cassette for 
replacing the 1.2 kb coding region (Nakai et al. 2003). Functional studies were 
performed on the mixed genetic background of 129S4/SvJae×C57BL/6J mice. 
Heterozygous mutant mice were phenotypically normal in both knockout lines. 
Our heterozygous mutant mice also show a grossly normal phenotype. 
Homozygous knockout mice showed neonatal mortality. In contrast, Pou3f3L423P 
homozygous mutant mice are viable and fertile; however they exhibit reduced 
body weight and a smaller size. Nakai et al. (2003) showed that one-day-old 
homozygous knockout mice have increased plasma urea and potassium levels 
with renal hypoplasia. Pou3f3L423P homozygous mutant mice show the same 
symptoms. The homozygous knockout mice showed developmental defects in the 
forebrain and the loop of Henle (McEvilly et al. 2002, Nakai et al. 2003). 
Therefore, further studies have to be carried out to assess potential developmental 
defects in brain and kidney of line Pou3f3L423P.  
Pou3f3L423P homozygous mutant mice show impaired renal functions with 
moderate polyuria and reduced excretion of uric acid. Nakai et al. (2003) observed 
decreased expression levels of Umod, Ptger3, Nkcc2, Kcnj1, and Bsnd in 
homozygous as well as heterozygous knockout mice. Umod associated kidney 
diseases have been described to exhibit reduced uric acid excretion (Bleyer et al. 
2003, Kemter et al. 2009, 2010). The data support the role of Pou3f3 in the 
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regulation of Umod and Nkcc2. The absence of hyperuricemia in mice with 
reduced renal excretion of uric acid might be due to the uricase activity present in 
rodents (Choi et al. 2005). In humans, up to now no mutations are reported for 
Pou3f3 (http://www.ncbi.nlm.nih.gov/omim). 
5.3 Line HST015 established by increased plasma urea levels 
Line HST015 harbouring a dominant mutation was initially established by 
increased plasma urea levels on the C3H genetic background. Linkage analysis 
using albino BALB/c inbred mice revealed the linkage of the mutant phenotype to 
the pigmented coat color of phenotypically mutant backcross mice. The albino 
coat color in BALB/c mice appears due to the recessive mutation Tyrc/c (94.5 Mb) 
on chromosome 7 (Detlefsen 1921). Therefore, the causative mutation in line 
HST015 was determined to be on chromosome 7 which was confirmed by the use 
of polymorphic markers on chromosome 7. Further breeding of backcrossed mice 
of the line HST015 showed a low number of mice with clear appearance of 
increased plasma urea levels. However, additional mutant phenotypes like 
decreased body weight as well as aggressive and/or hyperactive behaviour were 
observed. The reason for these phenotypic variations is not clear. The causative 
mutation of line HST015 is not yet identified.  
5.4 Line CLP001 exhibiting the mutation Gsdma3I359N 
The mutant phenotype of alopecia in line CLP001 was mapped to a defined region 
around 100 Mb on chromosome 11. Sequence analysis of the gene Gsdma3 (98.4 
Mb) revealed a T→A transversion which leads to the amino acid exchange from 
isoleucine to asparagine at position 359. Thus, the name of the line was 
designated as Gsdma3I359N. 
Gsdma3 is a member of the Gsdma gene family (Runkel et al. 2004). It has two 
variants: Gsdma3-001 is composed of 11 exons which code for a 464 aa 
polypeptide. Gsdma3-002 is composed of 10 exons which code for a 455 aa 
polypeptide. It is predominantly expressed in skin and gastric tissues (Tanaka et 
al. 2007).  
Upon searching the MGI database (http://www.informatics.jax.org) for mutant 
phenotypes, 2 targeted, 3 spontaneous and 4 ENU-induced alleles are found. 
Targeted alleles were generated by insertion of the L1L2_Bact_P vector 
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(http://www.informatics.jax.org). However, only cell lines are available to date. 
The spontaneous dominant mutation “defolliculated” (dfl) was observed in 
BABL/c mice which affects the skin and vision. A B2 element is inserted in exon 
7 near the 3' splice site at nucleotide 861 of the mRNA which leads to an in-frame 
stop codon and changes Ile at residue 260 to 260-ArgAspTrp-262 as well as 
inserting a 15 bp duplication of the mRNA sequence from nucleotide 846 to 860. 
Heterozygous mutant mice showed alopecia with corneal opacity (Porter et al. 
2002). The second spontaneous mutation occurred in C3H mice with 
semidominant inheritance. The mutation is characterized by a 6 bp insertion 
(AAGCGG) in exon 12 starting at nucleotide 1314 which results in a duplication 
of the codons 411 and 412 (GAA GCG, glutamic acid, alanine) to Glu Ala Glu 
Ala at 411–414. Mutant mice showed abnormal coat appearance (Runkel et al. 
2004). A third spontaneous mutation was observed in C57BL/10J×DBA/2J mice, 
which causes a G to A point mutation at nucleotide 1124 resulting in the A348T 
amino acid exchange. Mutant mice showed alopecia and corneal opacity (Tanaka 
et al. 2007).  
To date, 4 different ENU-induced dominant mutations of Gsdma3 have been 
identified.  These include Gsdma3Bsk, Gsdma3Fgn (BALB/c×C3H/HeH), 
Gsdma3Rco2 (C3HeB/FeJ) and Gsdma3M1Btlr (C57BL/6J). All mutations are single 
point mutations which result in an amino acid exchange. Mutant mice showed 
abnormal hair cycle and hair follicle degeneration resulting in hair loss and 
thickened, wrinkled skin as well as corneal opacities (Sun et al. 2009, and refs. 
therein). The corneal opacities in these mutants are caused by abnormalities of the 
sebaceous-like Meibomian gland of the inner eyelid (Porter et al. 2002).  
In line Gsdma3I359N, heterozygous mutant mice also show alopecia. The onset of 
hair loss starts from 3 weeks of age resulting in complete hair loss at 6 weeks of 
age. This is followed by the regeneration of a loose and spare complete hair coat 
until 8 weeks of age. Hair loss starts again and results in complete baldness at 14 
weeks of age in heterozygous mutants and at 10-11 weeks of age in homozygous 
mutants. Hair cycle morphogenesis is a developmental process in the mammal 
growth governed by numerous growth factors, cytokines, hormones, and other 
factors. The hair follicle morphogenesis is a repeated cycle of growth (anagen), 
regression (catagen) and rest (telogen) (Müller-Röver et al. 2001). Malfunctioning 
of the hair cycle leads to alopecia or hair loss and other hair related diseases. In 
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the two lines Gsdma3Rco2 and “defolliculated” (dfl), it was shown that the defect 
of the hair cycle occurred in the catagen phase at 3 weeks of age (Porter et al. 
2002, Runkel et al. 2004). In line Gsdma3I359N, the hair cycle is also disturbed in 
the catagen phase. However, there are also reports showing that the anagen phase 
is affected due to Gdsma3 mutations (Tanaka et al. 2007). In contrast, 
Gsdma3I359N mutant mice appear normal at one week of age. Gsdma3I359N mutant 
mice have normal eye grossly, however microscopically analysis has yet to be 
done to assess the corneal defects. In humans, one Gsdma gene is reported to date. 
It is expressed in the skin, hair follicle and gastrointestinal tract. However, there 
are no mutations of Gsdma reported in humans (Sun et al. 2009). 
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VI. SUMMARY 
Molecular genetic and phenotypic analysis of ENU-induced mutant mouse 
models for biomedical research 
In the phenotype-driven Munich ENU mouse mutagenesis project, the mutant 
lines HST014, HST011, and HST015 showing increased plasma urea levels as 
primary phenotype as well as line CLP001 exhibiting alopecia were established. 
The present study examined the causative mutations and the basal clinical 
chemical phenotypes of these four mutant lines.  
In line HST014 harbouring a dominant mutation, the causative mutation was 
mapped to chromosome 18. Sequence analysis of the candidate gene Kctd1 
revealed a T→A transversion which leads to the amino acid exchange from 
isoleucine to asparagine at codon 27. Therefore, the line was named as Kctd1I27N. 
Heterozygous mutant animals were viable and fertile whereas homozygous 
mutant animals showed early postnatal mortality. Clinical chemical blood analysis 
of 12-week-old heterozygous mutant animals showed increased levels of urea, 
creatinine, potassium, α-amylase, and lipase. Heterozygous mutant females 
showed hypercalcemia as well as a decreased body weight. Heterozygous mutant 
animals showed a moderate increase in the water intake as well as moderate 
polyuria and strong hypercalciuria.  
In line HST011 (= UREHR2) harbouring a recessive mutation, re-analysis of the 
linkage data led to the linkage of the causative mutation to chromosome 1. 
Sequence analysis of candidate gene Pou3f3 revealed a T→C transition, resulting 
in the amino acid exchange from leucine to proline at codon 423. The line name 
was designated as Pou3f3L423P. Clinical chemical blood analysis showed increased 
levels of urea and potassium in homozygous mutant animals of both genders. 
Homozygous mutant animals exhibited polyuria and decreased daily uric acid 
excretion. Homozygous mutant mice were viable and fertile and showed the 
reduction of the body weight, the nose-rump-length, and the absolute as well as 
relative kidney weight.  
Line HST015 harbouring a dominant mutation was initially established by 
increased plasma urea levels. The line was subsequently maintained using 
additional mutant phenotypes like decreased body weight as well as aggressive 
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and/or hyperactive behaviour. Linkage analysis using BALB/c inbred mice 
revealed that the causative mutation is linked to chromosome 7. The causative 
mutation is not yet identified. 
The dominant mutant line CLP001 showed alopecia as primary phenotype and the 
causative mutation was previously mapped on chromosome 11 around 100 Mb. 
Sequence analysis of the candidate gene Gsdma3 revealed a T→A transversion 
which leads to the amino acid exchange from isoleucine to asparagine at codon 
359. Thus, the name of the line was designated as Gsdma3I359N. Heterozygous 
mutant mice of both sexes showed onset of hair loss from the neck from 3 weeks 
of age resulting in complete hair loss at 6 weeks of age which was followed by 
regeneration of a loose and spare hair coat at 8 weeks of age. A second cycle of 
hair loss started from 9 weeks resulting in complete baldness at 14 weeks of age 
in heterozygous mutant mice and at 10-11 weeks of age in homozygous mutants. 
Homozygous mutant animals were viable and fertile.  
In total, the four ENU-induced mouse lines Kctd1I27N, Pou3f3L423P, HST015, and 
Gsdma3I359N were analyzed. The established mutant lines will contribute to the 
understanding of the functions of the genes involved.  
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VII. ZUSAMMENFASSUNG 
Molekulargenetische und phänotypische Untersuchung von ENU-induzierten 
Mausmutanten für die biomedizinische Forschung 
Im Rahmen des phänotypbasierten Münchener ENU-Mausmutageneseprojektes 
wurden die mutanten Linien HST014, HST011 und HST015 mit erhöhten 
Plasmaharnstoffwerten sowie die mutante Linie CLP001 mit Alopezie als 
primärem Phänotyp etabliert. Ziel der Arbeit war die Suche nach der ursächlichen 
Mutation sowie die basale klinisch-chemische und morphologische Untersuchung 
dieser vier mutanten Linien. 
In der dominant mutanten Linie HST014 wurde die Lage der ursächlichen 
Mutation auf eine definierte Region des Chromosoms 18 eingegrenzt. Die 
Sequenzanalyse des Kandidatengens Kctd1 erbrachte eine T→A Transversion, die 
zum Austausch der Aminosäure Isoleucin zu Asparagin an Kodon 27 des Proteins 
führt. Somit wurde die Linie mit Kctd1I27N bezeichnet. Heterozygot mutante Tiere 
beiderlei Geschlechts sind lebensfähig und fertil, wohingegen homozygot mutante 
Tiere eine frühzeitige postnatale Mortalität zeigen. Die klinisch-chemische 
Blutuntersuchung von zwölf Wochen alten heterozygoten Mutanten erbrachte 
erhöhte Werte für Harnstoff, Kreatinin, Kalium als auch für die Enzymaktivitäten 
der α-Amylase und Lipase. Heterozygot mutante weibliche Tiere zeigten auch 
Hyperkalzämie sowie ein verringertes Körpergewicht. Des Weiteren wiesen 
heterozygot mutante Mäuse einen moderaten Anstieg der täglichen 
Wasseraufnahme, eine moderate Polyurie und eine ausgeprägte Hyperkalzurie 
auf. 
In der rezessiv mutanten Linie HST011 (= UREHR2) wurden die bereits vor 
dieser Studie vorhandenen Kopplungsdaten nochmals überprüft. Diese 
Überprüfung führte dazu, dass die Lage der ursächlichen Mutation auf 
Chromosom 1 bestimmt wurde. Die Sequenzanalyse des Kandidatengens Pou3f3 
zeigte eine T→C Transition, die zum Austausch der Aminosäure Leucin zu Prolin 
an Kodon 423 des Proteins führt. Somit wurde die Linie mit Pou3f3L423P 
bezeichnet. Homozygot mutante Tiere beiderlei Geschlechts sind lebensfähig und 
fertil und zeigten als Zeichen einer gestörten Nierenfunktion erhöhte Blutwerte für 
Plasmaharnstoff und Plasmakalium sowie eine milde Polyurie und eine 
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verringerte Harnsäureausscheidung. Die morphologische Untersuchung erbrachte 
verringerte Werte für das Körpergewicht, die Körperlänge sowie für das relative 
Nierengewicht. 
Die dominant mutante Linie HST015 wurde initial mit Hilfe erhöhter 
Plasmaharnstoffwerte als primärem Phänotyp etabliert. Für die weitere Zucht der 
Linie sowohl auf dem genetischen Hintergrund des C3H-Inzuchtstammes als auch 
bei wiederholten Verpaarungen mit BALB/c-Inzuchttieren wurden zusätzliche 
phänotypische Auffälligkeiten wie verringertes Körpergewicht und/oder 
hyperaktives bzw. aggressives Verhalten als phänotypische Merkmale mutanter 
Tiere neu identifiziert und verwendet. Nach Verpaarung von phänotypisch 
mutanten Tieren auf dem genetischen Hintergrund des pigmentierten C3H-
Inzuchtstammes mit BALB/c-Albinoinzuchttieren wurde eine Kopplung der 
ursächlichen Mutation mit der Fellfarbe festgestellt, wodurch die Bestimmung der 
Lage der ursächlichen Mutation auf Chromosom 7 ermöglicht wurde und in 
weiteren Untersuchungen bestätigt wurde. Die Identifizierung der Mutation selbst 
steht noch aus. 
Die dominant mutante Linie CLP001 wurde mit Alopezie als primärem Phänotyp 
etabliert. Schon vorhandene Kopplungsdaten zeigten die Lage der ursächlichen 
Mutation auf Chromosom 11 bei ca. 100 Mb an. Die Sequenzanalyse des 
Kandidatengens Gsdma3 erbrachte eine T→A Transversion, die zum Austausch 
der Aminosäure Isoleucin zu Asparagin an Kodon 359 des Proteins führt. Somit 
wurde die Linie mit Gsdma3I359N bezeichnet. Homozygot mutante Tiere beiderlei 
Geschlechts sind lebensfähig und fertil. Heterozygote Mutanten zeigen drei 
Wochen p.p. den Beginn des Haarausfalles, der sich von der Nackengegend über 
das ganze Fell ausbreitet. Mit einem Alter von sechs Wochen tritt eine 
vollständige Alopezie bei diesen Tieren auf, die von einer regenerativen Phase 
gefolgt wird, so dass mit acht Wochen wieder ein schütteres Fell vorhanden ist. 
Eine Woche später beginnt der nochmalige Haarausfall, was zur vollständigen 
und permanenten Alopezie mit 14 Wochen p.p. führt. Bei homozygot mutanten 
Tieren tritt diese permanente Alopezie bereits nach 10-11 Wochen auf. 
Zusammenfassend wurden die vier ENU-induzierten Mauslinien Kctd1I27N, 
Pou3f3L423P, HST015 und Gsdma3I359N untersucht. Die Untersuchung dieser 
mutanten Linien trägt zum Verständnis der Funktion der am jeweiligen 
Krankheitsgeschehen beteiligten Gene bei. 
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